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Zusammenfassung 
Stickstoffmonoxid (NO) und cyclisches Guanosinmonophosphat (cGMP) sind 
Signalmoleküle, welche an zahlreichen physiologischen Prozessen beteiligt sind. NO 
stimuliert die lösliche Guanylylcyclase (NO-GC), die cGMP aus Guanosintriphosphat 
(GTP) synthetisiert. cGMP steuert physiologische Prozesse durch die Aktivierung von 
cGMP-Effektorproteinen wie cGMP-abhängige Proteinkinasen (cGKs), cyclische 
Nukleotid gesteuerte Kationenkanäle (cyclic nucleotide gated channels; CNG Kanäle) 
oder Phosphodiesterasen (PDE). Des Weiteren bauen PDEs cGMP zu GMP ab. Der 
cGMP Signalweg beeinflusst u.a. den Gefäßtonus, Knochenwachstum, 
Neurotransmission sowie Lernen und Gedächtnis. Im Gegensatz zum 
kardiovaskulären System, bei welchem die funktionellen Implikationen der NO-cGMP-
Signalkaskade bereits relativ gut erforsch sind, ist die Rolle dieses Signalsystems im 
Nervensystem weitgehend unbekannt. In dieser Arbeit haben wir Echtzeit-
Fluoreszenzmikroskopie und andere biochemische Methoden verwendet, um den NO-
cGMP-Signalweg im Nervensystem zu untersuchen. Des Weiteren haben wir eine 
Methode entwickelt, die eine zelltypspezifische Generierung von NO ermöglicht. 
Im ersten Teil der Arbeit wurde die Wechselwirkung zwischen cGMP und Ca2+, 
einem weiteren Signalmolekül, welches an neuronalen Funktionen beteiligt ist, weiter 
aufgeklärt. Für die simultane Messung beider Signalmoleküle in isolierten Kleinhirn 
Körnerzellen (cerebellar granule neurons; CGNs) haben wir ein mikroskopisches 
Echtzeit-Imaging Verfahren angewendet. Für die Visualisierung von cGMP wurde der 
Förster Resonanz Energietransfer (FRET)-basierte Sensor cGi500 verwendet. Für die 
Aufzeichnung von Ca2+ Signalen wurde der Ca2+-sensitive Farbstoff Fura-2 eingesetzt. 
cGMP Signale wurden in kultivierten CGNs oder akut isolierten Kleinhirnschnitten aus 
transgenen Mäusen gemessen, welche den cGi500 Sensor exprimierten. Die 
Präparate wurden mit dem NO-Donor DEA/NO stimuliert. DEA/NO erhöhte die 
intrazelluläre cGMP-Konzentration und verstärkte Glutamat-induzierte Ca2+ Signale in 
CGNs. Diese DEA/NO-induzierten Effekte fehlten in CGNs, welche aus NO-GC 
Knockout-Mäusen isoliert wurden. Darüber hinaus konnten die Glutamat-induzierten 
Ca2+-Signale in CGNs auch durch Applikation zweier unterschiedlicher cGMP-Analoga 
(8-Br-cGMP bzw. 8-pCPT-cGMP) verstärkt werden. Diese Analoga aktivieren cGMP-
Effektor Proteine wie cGKs oder CNG Kanäle. Mittels Western Blot Analysen mit 
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spezifischen Antikörpern konnten wir weder für cGK Typ I noch cGK Typ II eine 
Expression in unseren primären CGN-Kulturen nachweisen. Durch Zugabe von PDE-
Inhibitoren während der Messung von cGMP konnte gezeigt werden, dass CGNs 
cGMP über Zaprinast-sensitive PDEs abbauen, höchstwahrscheinlich durch PDE5 
und/oder PDE10, aber nicht über PDE1, 2 oder 3. Zusammenfassend beschreiben 
diese Daten eine cGK-unabhängige NO-cGMP-Signalkaskade, welche die Glutamat-
induzierten Ca2+-Signale in CGNs verstärkt. Diese Wechselwirkung zwischen cGMP 
und Ca2+ beeinflusst vermutlich Neurotransmitter-stimulierte Funktionen in CGNs. 
Im zweiten Teil der Arbeit wurde eine neue Methode entwickelt, die eine 
zelltypspezifische Generierung von NO ermöglicht. In vitro ist es bereits möglich den 
NO-cGMP Signalweg in ausgewählten Zelltypen zu untersuchen, jedoch bestand diese 
Möglichkeit bisher nicht für in vivo-Studien. Hier beschreiben wir eine neue Methode, 
welche auf der Verwendung von transgenen Mäusen und der Substanz -Gal-NONOat 
basiert. Diese Substanz setzt NO nur in Gegenwart des Enzyms β-Galaktosidase frei. 
Durch eine Cre/loxP gesteuerte Expression des lacZ-Gens, welches für die -
Galaktosidase kodiert, war es möglich, NO in spezifischen Zelltypen freizusetzen. 
Durch die Zugabe von -Gal-NONOat wurde nur in β-Galaktosidase exprimierenden 
glatten Muskelzellkulturen die intrazelluläre Konzentration von cGMP erhöht. Dies 
haben wir auch bei β-Galaktosidase exprimierenden Purkinje Zellen in 
Kleinhirnschnitten beobachtet. Weiterhin haben wir in einem transgenen Mausmodell, 
in dem β-Galaktosidase lediglich in Neuronen exprimiert wird, -Gal-NONOat 
verwendet, um Vasodilatation in vivo über neuronal generiertes NO herbeizuführen. 
Zusammengefasst haben wir in dieser Arbeit den prinzipiellen Nachweis der 
zelltypspezifischen Generierung von NO durch Verabreichung von -Gal-NONOat in 
Zellkultur, Gewebeschnitten und in vivo demonstriert. In Zukunft kann diese Methode 
dazu verwendet werden, um den Einfluss der Bildung von NO durch spezifische 
Zelltypen auf diverse biologische Prozesse zu untersuchen. 
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Summary 
Nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) are signal 
molecules associated with various physiological processes. NO stimulates soluble 
guanylyl cyclase (NO-GC), which synthesizes cGMP from guanosine triphosphate 
(GTP). cGMP triggers physiological processes through the activation of cGMP effector 
proteins such as cGMP-dependent protein kinases (cGKs), cyclic nucleotide gated 
(CNG) cation channels, or phosphodiesterases (PDE). Furthermore, PDEs degrade 
cGMP to GMP. The cGMP signaling pathway influences processes such as 
vasodilation, bone growth, neurotransmission, and learning and memory. However, in 
contrast to the cardiovascular system where the functional implications of NO-cGMP 
signaling have been well described, its detailed role in the nervous system is still 
relatively unknown. In this thesis, we have used real-time fluorescence microscopy 
and other biochemical methods to further investigate NO-cGMP signaling in the 
nervous system. In addition, we have developed a method that enables NO generation 
in a cell specific manner. 
In the first part of the work, we have studied the interaction between cGMP and 
Ca2+, another signaling molecule involved in neuronal functions. We used microscopic 
real-time imaging techniques for the simultaneous measurement of both signal 
molecules in isolated cerebellar granule neurons (CGNs). To visualize cGMP, the 
Förster Resonance Energy Transfer (FRET)-based cGMP sensor, cGi500, was used, 
whereas the Ca2+-sensitive dye Fura-2 was used to record Ca2+ signals. cGMP signals 
were measured in primary CGN cultures or acute cerebellar slices from transgenic 
mice expressing the cGi500 sensor. The preparations were stimulated with the NO 
donor DEA/NO. DEA/NO increased the intracellular cGMP concentration and 
augmented glutamate-induced Ca2+ signals in CGNs. These DEA/NO-induced effects 
were absent in CGNs isolated from NO-GC knockout mice. In addition, the glutamate-
induced Ca2+ signals in CGNs were enhanced by the application of two different cGMP 
analogues (8-Br-cGMP and 8-pCPT-cGMP, respectively). These analogues activate 
cGMP effector proteins such as cGKs or CNG channels. Western blot analyses with 
specific antibodies could not detect expression of cGK type I or cGK type II in our 
primary CGN cultures. The addition of PDE inhibitors during cGMP measurements 
showed that CGNs degrade cGMP via Zaprinast-sensitive PDEs, most likely via PDE5 
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and/or PDE10, but not via PDE1, 2 or 3. In summary, these data describe a cGK-
independent NO-cGMP signal cascade that increases glutamate-induced Ca2+ signals 
in CGNs. This interaction between cGMP and Ca2+ is thought to affect 
neurotransmitter-stimulated functions in CGNs.  
In the second part of this work, a new method was described that enables the cell 
type-specific generation of NO. It is already possible to study the NO-cGMP signaling 
pathway in specific cell types in vitro, but this possibility did not exist until now for the 
in vivo situation. Here, we describe a new method based on the use of transgenic mice 
and the substance -gal-NONOate. This compound releases NO only in the presence 
of the enzyme β-galactosidase. Through Cre/loxP controlled expression of the lacZ 
gene coding for -galactosidase, it was possible to release NO in specific cell types. 
The addition of -gal-NONOate increased the intracellular concentration of cGMP only 
in vascular smooth muscle cell cultures expressing β-galactosidase. A -gal-NONOate-
induced cGMP increase was also observed in β-galactosidase-expressing Purkinje 
cells of acute cerebellar slices. Furthermore, in a transgenic mouse model in which  
β-galactosidase is expressed only in neurons, we used -gal-NONOate to induce 
vasodilatation in vivo via neuronally generated NO. In summary, this work has 
demonstrated the principle of cell type-specific NO generation by administration of  
-gal-NONOate to cultured cells, tissue sections and mice in vivo. In the future, this 
method can be used to investigate the influence of NO generation by specific cell types 
on various biological processes.  
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1 Introduction 
 
1.1. Cellular signaling 
Biological systems receive information from the external environment which is 
then processed internally. This is also true at the cellular level. Extracellular molecules 
either bind to transmembrane proteins and initiate an intracellular signaling cascade or 
extracellular molecules themselves pass through the cell membrane and directly bind 
effector proteins inside the cell. These signal cascades induce physiological reactions 
such as vasodilation or neuronal firing and ultimately contribute to overarching 
behavioral processes like learning and memory. Advances in this field of research have 
resulted in a deeper understanding of biological processes and helped to produce new 
medications for humans. This thesis further investigates the interaction between the 
signaling pathways of nitric oxide (NO), cyclic 3’,5’-guanosine monophosphate 
(cGMP), and calcium (Ca2+).  
 
1.2. cGMP and the Nobel Prize 
The discovery of the second messenger cyclic adenosine monophosphate 
(cAMP) in 1958 by Rall and Sutherland [1] led to an explosive development of research 
on cyclic nucleotides and the intracellular second messenger cGMP has proven to be 
crucial for a variety physiological processes. For example, cGMP plays a vital role in 
vasodilation [2], bone growth [3], angiogenesis [4], hormone secretion [5], 
neurotransmission [6], sensory axon bifurcation [7], pain perception [8,9], learning and 
memory [10,11], among others. Since 1971, research relating to cyclic nucleotides and 
signal transduction has been awarded with at least five Nobel Prizes [12]. The prizes 
were awarded in 1971 to Dr. Sutherland Jr. for his work on hormones and cyclic 
adenosine monophosphate (cAMP) [13]; in 1992 to Dr. Fischer and Dr. Krebs for their 
work on protein kinases including cAMP regulated proteinkinases and their role in 
reversible protein phosphorylation [14]; in 1994 to Dr. Gilman and Dr. Rodbell for their 
work on G protein coupled receptors that regulate cAMP synthesis [15,16]; in 1998 to 
Dr. Furchgott, Dr. Ignarro and Dr. Murad for their findings about the role of NO and 
cGMP in vasodilation [17-21]; and in 2000 to Dr. Carlsson, Dr. Greengard, and Dr. 
Kandel for their contributions to cyclic nucleotide signaling in the nervous system [22-
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24]. This field of research has proven itself highly influential across disciplines.  
Alfred Nobel himself, the famous scientist and namesake of the Nobel Prize, 
helped to develop stable nitroglycerin in the mid-19th century and reportedly refused 
nitroglycerin as a treatment for his treat chest pain, so called angina pectoris [25]. NO 
releasing compounds have been used in the clinic since as early as 1867 to treat 
angina pectoris without an understanding of the underlying molecular mechanisms 
[25]. The 1998 Nobel Prize awarded to Dr. Furchgott, Dr. Ignarro and Dr. Murad is of 
particular interest to this doctoral thesis because they set the framework for NO-cGMP 
signaling. In their 1977 publication, Murad and colleagues demonstrated that certain 
nitric oxide releasing compounds, such as sodium nitroprusside, nitroglycerin, sodium 
azide and hydroxylamine increased cGMP levels via activation of the enzyme NO-
sensitive guanylyl cyclase (NO-GC) [21]. A few years later in 1980, Furchgott and 
colleagues reported that a vasodilating substance was released from the endothelial 
layer of vessels upon exposure to acetylcholine. The paper termed the substance 
endothelium-derived relaxing factor (EDRF) [20,26]. Later work by Ignarro revealed 
that NO and EDRF are indeed one and the same [19], leading to the researcher’s 
shared 1998 Nobel Prize for Physiology or Medicine. Since then a great deal of work 
conducted on NO has detailed the relevant enzymes and molecules responsible for its 
wide-ranging physiological effects. The following section outlines the relevant 
molecular players in cGMP signaling.  
 
1.3. NO-cGMP signal transduction 
The enzymes that catalyze NO synthesis are known as nitric oxide synthases 
(NOSs) and consist of three known members: endothelial NOS (eNOS), neuronal NOS 
(nNOS) and inducible NOS (iNOS) [27,28]. NOS catalyzes the conversion of L-arginine 
and oxygen into NO and consists of a bidomain structure containing an N-terminal 
oxygenase domain that is linked to the C-terminal reductase domain by a 
Ca2+/calmodulin-recognition site and has binding sites for heme, tetrahydrobiopterin 
(BH4) and L-arginine [27,28]. The C-terminal reductase domain contains binding sites 
for the cofactors flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and 
nicotinamide adenine dinucleotide phosphate (NADPH) [29]. eNOS is present in 
endothelial cells including those in the central nervous system (CNS) [27]. iNOS is 
associated with immune responses and has been reported in macrophages and 
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microglia [27,29]. nNOS generates NO in the central nervous system (CNS) and in 
specific tissues outside the CNS, for example in skeletal tissue. Both nNOS and eNOS 
demonstrate calcium-dependent regulation, while iNOS is calcium-insensitive [29,30].  
nNOS was the first NOS to be purified and cloned and it is ubiquitously 
expressed throughout the CNS where it serves as the main source of NO in the brain 
[29]. Notably, the N-terminal 220 amino-acids of nNOS are distinct from the other NOS 
isoforms. The N-terminus of nNOS contains a binding site for the post synaptic density 
protein 95 (PSD-95), termed the PDZ binding domain. The term PDZ comes from the 
first letters of the first three proteins discovered with said domain, namely PSD-95, 
drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein (zo-1) 
[29]. PSD-95 binds to the C-terminus of N-methyl-D-aspartate (NMDA) receptors and 
has been evidenced to provide a platform for the functional coupling of nNOS and 
NMDA receptors [31,32]. Researchers have postulated that agonist-induced NMDA 
receptor stimulation activates nNOS and thus NO generation in neurons pointing to a 
neuronal activity dependent modulation of cGMP signaling. 
cGMP is generated via activation of guanylyl cyclases (GCs) which exist in two 
families: the NO-GC proteins, primarily found in the cytosol, and the transmembrane 
proteins, particulate guanylyl cyclases (pGCs). NO activates NO-GC [33,34], while 
natriuretic peptides, guanylin, uroguanylin, or enterotoxins activate pGC [35,36]. The 
enzyme GC-A binds atrial and B-type natriuretic peptide (ANP, BNP), while GC-B binds 
C-type natriuretic peptide (CNP), and GC-C binds guanylin and uroguanylin [35]. The 
pGC stimulated pathway is also essential for key neuronal processes. For example, 
the CNP/GC-B/cGMP pathway is essential for sensory axon bifurcation in the 
developing spinal cord and is associated with axon guidance [7,37]. However, the main 
focus of this work is NO-cGMP signaling.  
The mammalian NO-GC is a heterodimeric hemoprotein with two known NO-
GC isoforms, 11 and 21 [38]. Both isoforms exist in most tissues, but research has 
shown that while the 21 isoform is more prominently expressed in the brain in general 
[39], some neuronal regions express the 2 or1 isoforms preferentially [40-43]. This 
suggests that there could be differential cGMP signaling facilitated by distinct NO-GC 
isoform distribution. The 2 isoform has an additional PDZ binding domain, which could 
facilitate its localization to the presynapse [44]. Another isoform of the  subunit has 
been reported termed 2, but it appears to be physiologically inert and is considered to 
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be a pseudogene [39]. NO-GC is primarily found in the cytosol and is the only known 
physiological receptor of NO in mammals. NO activates NO-GC via binding to the 
heme group of the 1 subunit at the axial ligand histidine 105 [45] and the heme-binding 
motif tyrosine 135 and arginine 139 [46]. Upon NO binding, the heme Fe2+ forms 
nitrosyl-heme [47], disrupting the histidine 105-iron bond resulting in enzyme activation 
and subsequent conversion of GTP into cGMP [45,48-50].  
While this work focuses on NO as an activator of NO-GC, it is important to note 
that NO also can induce cGMP independent effects. For example, NO can generate 
reactive oxygen species, such as superoxide anion (⋅O2−) or peroxynitrite (ONOO−), 
both of which have been shown to cause oxidative injury [51]. This happens when 
peroxynitrite causes oxidative stress to DNA, proteins, or lipids. For example, these 
reactions can damage endothelial tissue and contribute to cardiovascular disease [51]. 
For these reasons, control experiments with tools that disrupt the function of NO-GC 
are essential to discriminate between the NO-GC mediated effects and NO-GC 
independent effects of NO. 
cGMP signaling imparts its physiological effects via three main types of 
effectors: cGMP-dependent protein kinases (cGKs), cation channels, such as cyclic 
nucleotide gated (CNG) channels, and cGMP-regulated phosphodiesterases (PDEs) 
(Figure 1).  
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Figure 1. cGMP signaling and its physiological effects. 
Pictured are cGMP generators (green), effectors (red), and some downstream pathways and cellular 
functions of cGMP signaling (grey boxes). The blue text represents areas where cGMP-modulating 
drugs act. The lower part shows some current (blue) and potential future (black) indications for drugs 
that modulate cGMP levels or cGMP effector pathways. BNP, B-type natriuretic peptide; cGKs, cGMP 
dependent protein kinases; IRAG, IP3 receptor-associated cGKIβ substrate; PDEs, 
phosphodiesterases; pGC, particulate guanylyl cyclase; sGC, soluble guanylyl cyclase (also known as 
NO-GC); VASP, vasodilator-stimulated phosphoprotein. Adapted from Feil and Kemp-Harper, 2006 [52]. 
 
The cGKs are part of the serine/threonine kinase family and consist of three 
isoforms: cGK type I and I (cGKI/, and cGK type II (cGKII), these proteins are 
homodimers and also sometimes termed ‘protein kinase cGMP’ (PKG1 and PKG2) 
[53]. In this thesis, they will always be referred to as cGKs. The cGKs have two cGMP 
binding sites [54] and the N-terminus acts as a targeting sequence that influences the 
subcellular location of the different isoforms, where cGKI is generally in the cytosol and 
cGKII at the membrane [55,56]. cGKI is highly expressed in smooth muscle, 
cerebellum, hippocampus, dorsal root ganglia, neuromuscular junctions, kidney, and 
platelets, and in lower amounts in other tissues [57,58]. cGKII undergoes 
myristoylation of the Gly2 residue and is located at the plasma membrane. cGKII has 
been identified in the brain, kidney, adrenal cortex, lung, bone, and other tissues 
[56,59,60]. Some research suggests distinct functions of the different isoforms [61], but 
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studies also report that many cGK substrates are phosphorylated by both cGKI and 
cGKII suggesting that substrate specificity for one isoform is not pronounced in this 
system [62,63]. That said, differential expression of the cGK isoforms has been 
observed and cGKI and cGKII are generally not found in the same cell [56,58]. The 
cGKs also contain N-terminal leucine zipper motifs that form the catalytically active 
cGK homodimers. Upon cGMP binding, cGK undergoes a conformational change that 
results in the release of an inhibitory pseudo-substrate domain, located at the N-
terminus, enabling the phosphorylation of substrate proteins [54,64]. The cGK 
substrates exist in a diverse range of tissues and are essential for the regulation of 
functions, such as cell contractility, motility, proliferation, differentiation, and cellular 
secretion [55,56]. The typical substrates of cGKs include certain G proteins, ion 
channels, and cytoskeletal-associated proteins [55]. 
cGMP can also influence CNG channels, which are found in the plasma 
membrane and belong to the superfamily of pore-loop cation channels [65,66]. They 
form heterotetrameric complexes consisting of two or three different subunits. The six 
different CNG channel genes encode four A subunits (A1, A2, A3, A4) and two B 
subunits (B1 and B3) [66]. The six homologous proteins display differential tissue 
expression patterns and varying binding affinities to cGMP and cAMP [66]. The 
channels open upon binding of cyclic nucleotides to the protein’s intracellular region. 
They are permeable to Na+, K+ and Ca2+ and show voltage-dependent opening 
probabilities which are shifted by cyclic nucleotide binding [65]. They have been 
detected in tissues, such as olfactory bulb, retina, brain, kidneys, and sperm cells [65]. 
CNG channels are present throughout the mammalian CNS and have been implicated 
in modulating neuronal synaptic function [65,67,68]. 
cGMP also interacts with PDEs, which are responsible for cyclic nucleotide 
degradation. The superfamily of PDE enzymes consists of eleven gene families with 
some families consisting of multiple members [69-71]. There are a total of 21 PDE 
genes that also vary with alternative initiation sites and alternative splicing, which 
generates over 50 different PDE proteins. PDEs hydrolyze both cGMP and cAMP to 
their respective non-cyclized forms. PDEs 5, 6, and 9 are cGMP-specific; PDEs 4, 7 
and 8 are cAMP-specific; and PDEs 1, 2, 3, 10, and 11 degrade both cAMP and cGMP 
but with varying efficiency [69-71]. PDE activity is regulated by cAMP or cGMP binding. 
Allosteric binding sites for both cAMP and cGMP known as GAF domains also exist 
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(cGMP-specific phosphodiesterases, Anabaena adenylyl cyclases, and Escherichia 
coli FhlA) and have been identified in PDEs 2, 5, 6, 10, and 11 [69,72]. The existence 
of GAF domains has resulted in hypothesized cGMP-cAMP crosstalk [73]. Indeed, 
researchers have reported that the NO-cGMP pathway inhibits transient cAMP signals 
via activation of PDE2 in striatal neurons demonstrating cGMP-cAMP crosstalk [74]. 
Furthermore, cAMP binding to PDE10 has been associated with increased cGMP 
levels [75]. Regarding the other PDEs with GAF domains, PDE 6 is almost exclusively 
discussed in the context of photoreceptor cells [69], while PDE 5 is reported as 
functionally relevant for the regulation of cGMP levels in smooth muscle cells, the 
heart, brain and elsewhere [76,77]. The PDE5 GAF domain has been well studied and 
a negative feedback loop regulating cGMP levels has been reported at higher cGMP 
concentrations [78]. This appears to occur due to allosteric binding of cGMP to PDEs 
which activates the catalytic sites resulting in cGMP hydrolysis [78]. Nearly all of the 
eleven PDE families have been reported in the CNS [69,79,80]. Research investigating 
PDEs in rodents and humans has suggested that PDEs 9, 10, and 11 play a role in 
neurological diseases, such as PDE9 in bipolar affective disorder [81], PDE10 in social 
interaction, schizophrenia, and bipolar disorder [82-84], and PDE11 in major 
depression [85]. The following sections discuss cGMP-modulating medications, NO-
cGMP signaling in the nervous system, and the modern methods used to investigate 
cGMP signaling. 
 
1.4. cGMP-modulating drugs for humans 
In the past decades, the cGMP signaling cascade has proven itself highly 
drugable, with the approval of various cGMP-modulating drugs for humans and many 
more cGMP-modulating substances are in late stage clinical development (Table 1). 
With greater understanding of the cGMP signaling pathway, it will be possible to design 
new medications that target different aspects of the signaling cascade. These targets 
include: NO releasing compounds; GC stimulators and activators; inhibitors of 
neprilysin, a natriuretic peptide degrading enzyme; PDE inhibitors and more could be 
discovered with further research. The PDE5 inhibitor sildenafil, one of the most famous 
medications, known commercially as Viagra, is prescribed to treat erectile dysfunction. 
Further PDE5 inhibitors exist to treat diseases in different therapeutic areas, such as 
cardiology [86]. Other cGMP-modulating medications include the GC-C agonist 
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linaclotide to treat chronic idiopathic constipation and irritable bowel syndrome, as well 
as NO-GC stimulators (e.g. Riociguat, IW-1701, and Ataciguat) which are designed to 
treat diseases, such as pulmonary hypertension, sickle cell anemia, and 
cardiovascular disease. Many companies have additional NO-GC stimulators in human 
clinical trials [87]. Pharmaceutical companies such as Bayer, Ironwood 
Pharmaceuticals, Abbot Labs, GlaxoSmithKline, Yung-Shin Pharmaceutical, Novartis, 
Boehringer Ingelheim, Sanofi-Aventis and others have invested time and money into 
the research and development of cGMP-modulating medications [87]. Indeed, 
preclinical and clinical research is currently underway on a multitude of cGMP-
modulating drugs to determine their therapeutic value as treatments for diseases such 
as cardiovascular disease, sickle cell anemia, dwarfism, and others (Table 1).  
 
 
Table 1. Selected cGMP-modulating medications available or in development for human use.  
cGMP-modulating medications act on various parts of the cGMP signaling cascade and are approved 
for use in several therapeutic areas. The table provides examples of cGMP-modulating medications that 
are in late-stage clinical development or available in the clinic. See cited papers for more information 
[52,86-97]. 
Drug Mechanism of action Status Therapeutic use Citation 
Ataciguat NO-GC stimulator Phase II Cardiovascular [87,90] 
Cenderitide GC-A and GC-B activator Phase II Cardiovascular [92] 
IW-1701 NO-GC stimulator Phase II Sickle cell anemia [87] 
Linaclotide GC-C agonist In clinical use Irritable bowel syndrome [93,94] 
Riociguat NO-GC stimulator In clinical use Pulmonary hypertension [87,97] 
Sacubitril Neprilysin inhibitor In clinical use Cardiovascular [95] 
Sildenafil PDE5 inhibitor In clinical use Erectile dysfunction and 
pulmonary hypertension 
[86] 
Vosoritide CNP analogue Phase II Dwarfism [96] 
 
 
1.5. NO-cGMP signaling in the nervous system 
Initially, the scientific community did not accept NO as a true neurotransmitter 
because it is not stored within the brain like other neurotransmitters. Perhaps even 
more perplexing was the idea that an unstable, gaseous molecule capable of diffusing 
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across both aqueous and lipid environments is able to serve a targeted function [98]. 
NO is now recognized as a neurotransmitter and NO-cGMP signaling has been 
documented in numerous regions of the CNS [6-8,10,30,98]. Both NO-GCs and pGCs 
have been reported in various neural regions including the cerebellum, striatum, 
cortex, olfactory bulb, and spinal cord [10]. Downstream targets of cGMP, including 
cGKI and cGKII, have been described in diverse areas of the nervous system 
[57,60,99]. CNG cation channels and PDEs have also been demonstrated to play a 
role in cGMP signaling in the CNS [65,67,69]. The NO-cGMP signaling pathway is 
implicated in neurological disorders, such as depression, addiction, schizophrenia, and 
cognition [10].  
Modulation of cGMP signaling in the CNS alters learning and memory, as 
investigated with experimental paradigms, such as long-term potentiation (LTP) and 
long-term depression (LTD) [11,100]. LTP is a strengthening of synaptic 
communication between two neurons that persists long-term. LTD is an activity-
dependent synaptic weakening that lasts for hours or longer. Both LTP and LTD are 
paradigms used to investigate learning and memory, or so-called synaptic plasticity. 
Learning and memory occurs via changes in synaptic efficiency contingent upon the 
relative frequency at which neurons fire together [101]. This process is referred to as 
Hebbian plasticity, named after the researcher Donald Hebb who first proposed the 
theory [102]. As written by Hebb, ‘When an axon of cell A is near enough to excite a 
cell B and repeatedly or persistently takes part in firing it, some growth process or 
metabolic change takes place in one or both cells such that A's efficiency, as one of 
the cells firing B, is increased’ [103]. Or as succinctly paraphrased by Carla Shatz ‘what 
fires together, wires together’, often quoted as ‘neurons that fire together, wire together’ 
[104,105].  
As it currently stands, the hypothesis of NO-cGMP signaling in the brain begins 
with NO generation by nNOS, or perhaps eNOS. Then, cGMP is elevated by activated 
NO-GCs, whereby cGMP targets downstream molecules and ultimately initiates 
receptor recruitment to, or removal from, the synaptic membrane. Examples of such 
receptors are NMDA receptors or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors. Their addition to or removal from the synaptic membrane 
modulates synaptic firing sensitivities depending on the brain region (Figure 2). Due 
to the gaseous nature of NO, a signaling effect has been proposed whereby NO is 
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synthesized in the synapse and diffuses across the synaptic cleft to the other synapse 
elevating cGMP. Depending on the direction, this process is termed retrograde or 
anterograde NO signaling (Figure 2). 
 
 
 
 
Figure 2. Current hypothesis of the role of cGMP signaling in synaptic plasticity. 
NO is generated by a Ca2+/calmodulin-regulated nNOS or possibly by eNOS from endothelial cells or 
neighboring neurons (indicated by the question marks). Cellular cGMP concentrations are elevated by 
sGC (also known as NO-GC) via activation by NO. The cGMP-dependent protein kinases (cGKI and 
cGKII) and members of two ion channel families (cyclic-nucleotide gated channels (CNG) and 
hyperpolarization-activated cyclic nucleotide-gated channels (HCN)) have been identified as 
downstream effectors of cGMP in synaptic plasticity. Depending on the brain region, NO is either 
produced in the postsynapse and then diffuses into the presynaptic terminal (retrograde signaling) or 
vice versa (anterograde signaling). Retrograde NO signaling has been implicated in LTP in the 
hippocampus and amygdala. Anterograde NO signaling has been proposed for LTD in the cerebellum. 
In this figure, the cGKI in the postsynapse may enhance the internalization of AMPA receptors indirectly 
through phosphorylation of G-substrate (not shown), which, in its phosphorylated form, serves as an 
inhibitor of protein phosphatases. This increases the level of phosphorylated AMPA receptors, which 
are removed from the postsynaptic membrane, ultimately, resulting in LTD of synaptic transmission. 
Adapted from Kleppisch and Feil, 2009 [10].  
 
In addition to learning and memory, the NO-cGMP pathway might be involved 
in a process known as neurovascular coupling. Neurovascular coupling refers to 
changes in neuronal activity that result in modulated local blood perfusion and thus 
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changes in glucose and oxygen supply (Figure 3). Disruption of this process has been 
associated with various neurological diseases such as stroke, Alzheimer’s Disease 
and cortical spreading depression [106,107]. While the exact molecular players 
involved in neurovascular coupling remain controversial, one candidate is NO 
[108,109]. Given the gaseous nature of NO, it could be synthesized by nNOS in 
neurons and diffuse across membranes to induce vasodilation in nearby vessels via 
elevation of cGMP. Previous work has demonstrated a relationship between NO, 
cerebral blood flow and oxygen levels in hippocampal slices [108]. Nevertheless, the 
significance of NO in neurovascular coupling in vivo is unclear.  
 
 
 
Figure 3. A model of neurovascular coupling  
The model depicts the sequence of events leading to NO-modulated neurovascular coupling. NO is 
synthesized by nNOS in the neuron upon glutamate-induced stimulation of NMDA receptors and 
subsequent nNOS activation. NO then diffuses to nearby vessels, activates NO-GC (pictured sGC), 
which then elevates cGMP levels. cGMP then activates downstream targets and ultimately induces 
vasodilation. The resulting increased cerebral blood flow (CBF) provides neurons with more nutrients 
such as oxygen and glucose. Adapted from Lourenço et. al., 2014 [108].  
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Although the cGMP signaling cascade has been widely reported in the nervous 
system, its functional influence is understood in limited contexts. One can argue that 
the dearth of data on cGMP signaling in the CNS is a large hindrance to the 
development of cGMP-modulating medications for neurological disorders. Given the 
success of cGMP-modulating medications in other therapeutic areas (Table 1) and the 
clear relevance of cGMP signaling to neurological processes, it is imperative that 
researchers continue to delineate the cGMP signaling pathway in the CNS. Such 
research is of high clinical relevance, given that companies are developing CNS active 
cGMP-modulating molecules. For example, Ironwood pharmaceuticals has a CNS-
penetrant NO-GC stimulator in preclinical development named IW-6463 [87]. 
Ultimately, a detailed understanding of NO-cGMP signaling is necessary to assess 
specificity and off-target effects of such treatment avenues. In the following sections, 
a number of tools will be presented that enable cell type specific generation of NO and 
the real-time visualization of cGMP in living cells, tissues, and animals allowing for 
improved spatiotemporal investigation of NO-cGMP signaling.  
 
1.6. Biological models to investigate NO-cGMP signaling  
Researchers employ different models to investigate cell signaling pathways. 
Cell culture, tissue slices, and in vivo models all have their advantages and 
disadvantages. In this thesis we utilized primary vascular smooth muscle cell (VSMC) 
cultures isolated from mice. VSMCs are located in blood vessels and can contract to 
regulate blood flow. The vessel wall consists of three layers: tunica adventitia, tunica 
media, and tunica intima. The adventitial layer is made up of connective tissue; the 
intimal layer contains a layer of endothelial cells; the medial layer contains VSMCs. 
The endothelial cells generate NO which diffuses into the VSMCs and stimulates 
NO-GC resulting in cGMP elevation [2]. Then cGMP activates cGKI, which likely results 
in phosphorylation of several substrate proteins, although the in vivo relevance of some 
substrates is contested, and ultimately vasodilation [62,110]. NO-cGMP signaling has 
been extensively investigated in VSMCs [2], but its role in the CNS is less well 
documented. 
For our neuronal cell model, we used primary cerebellar granule neurons 
(CGNs) isolated from mice. CGNs are the most abundant neuronal cell type in the 
brain. In the cerebellum, more than 90% of the neurons are granule neurons [111]. 
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They are small with a soma of about 10 μm in diameter containing a large nucleus that 
nearly encompasses the entire soma. CGNs usually have four extending dendrites that 
form synaptic connections with mossy fibers and Golgi cells in specialized structures 
referred to as glomeruli [112]. CGN axons, called parallel fibers, interact with another 
neuronal cell type known as Purkinje cells. CGNs are an established cell model in 
laboratories across the world and NO-cGMP signaling has been reported in these cells 
[111,113-116]. While they are highly useful in the laboratory setting, cell culture models 
are not always representative of the in vivo situation. For this reason, we also used 
acute brain tissue slices and in vivo models to investigate NO-cGMP signaling in more 
biologically relevant models.  
 
1.7. Real-time imaging of signal transduction with biosensors 
Endpoint assays such as Western blots, mRNA analysis, or immunoassays are 
often used to investigate signaling cascades. These techniques are limited in that they 
can only view living systems at single time points. Excitingly, live-cell microscopy has 
advanced in recent decades and numerous biosensors have been developed to 
visualize the spatiotemporal dynamics of signaling molecules in living cells and animals 
in real time [117-119]. 
Traditionally, cGMP has been measured via enzyme-linked immunosorbent 
assay (ELISA) or radioimmunoassays, but these are end-point assays meaning they 
only provide single values and, due to technical restrictions, their temporal resolution 
is low and they lack tissue or subcellular spatial information about the dynamic 
signaling processes [120,121]. Recently, the Feil lab has generated mouse lines that 
express fluorescent biosensors capable of measuring changes in intracellular cGMP 
concentrations ([cGMP]i) with high spatiotemporal resolution in real time in living cells, 
tissues, and mice providing a valuable tool to further investigate this cascade 
[118,122,123]. The new technology uses a Förster resonance energy transfer (FRET)-
based cGMP sensor with an EC50 of 500 nM (cGi500) created by Russwurm and 
colleagues (Figure 4) [124]. The FRET phenomenon was first described by Theodor 
Förster in 1946 and operates based on radiationless energy transfer from a light 
sensitive donor fluorophore to a light sensitive acceptor fluorophore in a proximity and 
orientation dependent manner [125]. cGi500 is a ratiometric sensor that allows for 
quantitative measurements of [cGMP]i. The sensor consists of cGMP binding domains 
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from cGKI flanked by a cyan and yellow fluorescent protein (CFP and YFP). When 
cGMP binds to cGi500, a conformational change occurs distancing and/or reorienting 
the two fluorescent proteins and reducing FRET. Specifically, binding of cGMP causes 
a decreased YFP emission (535 nm) and increased CFP emission (480 nm) in 
response to CFP excitation (445 nm) (Figure 4). The ratio of CFP/YFP emission is 
used as a measure of FRET efficiency and thus [cGMP]i. Different transgenic knock-in 
mouse lines have been generated that express the cGMP sensor in different forms, for 
example cytosolic [118] or membrane bound. Furthermore, a cGi500 variant with a 
stop cassette (mT/cGi500-L2) has been developed that expresses the membrane-
targeted tandem-dimer tomato red fluorescent protein (mT) before Cre recombination 
and contains the L2 allele, where “L2” stands for “two loxP sites” and the stop cassette 
is excised upon recombination. By using cell specific Cre mouse lines, it is possible to 
visualize cGMP in specific cells with the cGi500 sensor.  
 
 
Figure 4. FRET-based cGMP sensor cGi500. 
cGi500 is a ratiometric cGMP biosensor consisting of the cGMP-binding domain of bovine cGKI flanked 
by CFP and YFP. The left image depicts the sensor in the non-cGMP bound state where FRET efficiency 
is high. The right image depicts the cGMP bound state. Binding of cGMP causes a conformational 
change that reorients and/or distances CFP and YFP. Thereby, after excitation of CFP light emission 
from YFP at 535 nm is reduced, while emission from CFP at 480 nm is increased. The ratio of emission 
at 480 nm and 535 nm (F480/F535) is used as a measure of FRET efficiency, which represents the 
[cGMP]i. Adapted from Thunemann and Wen et. al., 2013 [118]. 
 
To visualize changes of the intracellular Ca2+ concentration ([Ca2+]i), this work 
employed the fluorescent Ca2+ indicator Fura-2-acetoxylmethyl ester (Fura-2-AM). 
This and other cell permeable Ca2+ sensors have been developed by the Tsien group 
and others since the 1980s [126]. Fura-2 itself it not membrane permeable but further 
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chemical modification by researchers led to Fura-2-AM, which is membrane-
permeable [126]. When Fura-2-AM enters the cell, it is de-esterified by cellular 
esterases and the resulting Fura-2 then binds intracellular Ca2+ (Figure 5A). Fura-2 
undergoes a shift in excitation maximum from 370 nm to 340 nm upon Ca2+ binding, 
while the emission maximum remains at 515 nm independent of Ca2+ binding (Figure 
5B) [126]. The Fura-2-AM sensor was chosen because its fluorescence spectrum is 
compatible with cGi500, it is cell permeable, ratiometric and commonly used in 
neuronal cultures. By combining Fura-2 and cGi500, both Ca2+ and cGMP can be 
visualized in the same cell simultaneously to investigate potential crosstalk between 
these signaling molecules.  
 
 
 
 
Figure 5. Fura-2-AM for intracellular Ca2+ imaging. 
(A) The Ca2+ indicator Fura-2 is a Ca2+-chelating agent and fluorophore. Intracellular free Ca2+ (red) 
binds to Fura-2 and induces a conformational change which modulates the excitation maximum of 
Fura-2 from 340 nm to 370 nm while emission remains between 505-520 nm. Adapted from Grienberger 
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and Konnerth, 2012 [127]. (B) Ca2+ free Fura-2 exhibits an excitation maximum at 370 nm (green, Ca2+-
free) and an emission peak maxium at 515 nm (purple, Ca2+-free). Upon Ca2+ binding, Fura-2’s excitation 
maximum changes to 340 nm (blue, Ca2+-saturated) while the emission peak remains at 515 nm (red, 
Ca2+-saturated). The [Ca2+]i correlates with the F340/F380 emission ratio. Credit for Figure B, Markus 
Wolters. 
 
 
1.8. Transgenic mice and the Cre/loxP system  
Transgenic mice are an essential tool to investigate signaling cascades in 
mammals. Genetic analysis suggests that about 80% of mouse genes have a single 
orthologue in humans and that less than 1% of mouse genes have no human 
homologue currently detected [128,129]. Additionally, large mouse breeding colonies 
are possible to maintain given the relative low costs compared to other mammalian 
species, a plethora of literature exists on the characterization of mouse lines, and 
genetic modification techniques are highly advanced for mice. A world-wide effort to 
develop a knock-out mouse line for every gene to determine its biological function is 
underway [130]. Excitingly, new gene editing technologies, such as CRISPR-Cas9, 
make it possible to essentially genetically modify any organism and it is likely that new 
experimental animal models will emerge in the coming years [131,132]. 
The combination of genetic mouse models and pharmacological substances 
allows for the detailed elucidation of cell signaling cascades. However, using 
transgenic mice that have genetic modifications from conception can influence or even 
halt the animal’s development [133]. For this and other reasons, it is desirable to have 
a genetic modification of interest controlled in both time and space, also known as 
spatiotemporal control. Such genetic modification is possible with the cyclization 
recombination (Cre) enzyme, which recombines two 34 bp-long, semi-palindromic 
DNA sequences referred to as 'loxP' sites, named after the locus of crossing-over (X-
over) in P1 bacteriophages [134]. Upon recombination, the genetic sequence between 
the loxP sites can be removed or inverted depending on the orientation of the loxP 
sites (Figure 6).  
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Figure 6. Cell type specific gene expression with the Cre/loxP system.  
The Cre/loxP-directed gene modification occurs by flanking an exon of the gene of interest with two loxP 
(black triangles) sites and then Cre excises that portion of the DNA resulting in genetic modification. A 
possible strategy shown here is to place the gene of interest (e.g. lacZ) under the control of a ubiquitous 
promoter, such as ROSA26 (R26), with a floxed stop codon (red box). Cell specific expression of lacZ 
can be achieved by cell type specific expression (blue oval) of a Cre recombinase. In this mouse, lacZ 
in expressed in specific cells and -gal-NONOate is cut by the resulting enzyme -galactosidase. This 
then generates NO only in the cells where Cre is active. Lai Wen (Interfaculty Institute of Biochemistry, 
University of Tübingen) provided the mouse image.  
 
Research conducted by Feil, Metzger, Chambon and others led to the 
development of ligand-activated CreERT and CreERT2 fusion proteins, which bind the 
synthetic drug 4-hydroxytamoxifen (4-OHT), but not estradiol, the endogenous 
estrogen receptor ligand [135-137]. By using transgenic mice with cell type specific 
expression of CreER recombinases and timed exposure to tamoxifen, the prodrug of 
4-OHT, highly specific spatiotemporal control over gene expression is possible. It is 
important to note that, as with any genetic tool, the Cre/loxP system is not always inert 
in mouse lines as indicated by research demonstrating differences between Cre mouse 
lines and wild type mouse lines, for example on behavior [138,139]. The influence of 
the Cre/loxP system can be controlled by comparison of transgenic Cre mice to wild 
type mice.  
Numerous tissue specific Cre mouse lines, also known as a ‘Cre-zoo’, are 
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available and can be bred with other genetically modified mice, for example, Cre-
activatable lacZ mouse lines. Laboratories with mouse generation expertise can also 
develop specific mouse lines for their unique experiments as was done by Thunemann, 
Wen and colleagues [118]. A ‘Cre-zoo’ allows for interesting genetic combinations, for 
instance cell specific lacZ expression selectively in the Purkinje cells of the cerebellum. 
Furthermore, live cell microscopy is an advantageous method when investigating 
signal cascades with these mouse models. For example, we have a microscopy setup 
that functions as a continuous flow system and facilitates the application and wash out 
of substances to measure dynamic cell responses (e.g. [cGMP]i) in real-time. 
 
1.9. A new method to induce cell type specific NO generation 
Current research investigating the NO signaling pathway generally employs 
global elevators of NO. That is to say, the current NO donors that are used to increase 
biological levels of NO act indiscriminately on all tissues and cell types [140]. Even if 
one uses stereotactic guided injection of a NO-releasing substance to target a specific 
neuronal region, all cell types are affected, which makes conclusions about the role of 
NO in specific cell types uncertain. For example, the NO pathway in Purkinje cells in 
the cerebellum is thought to play a role in LTD [100], but global NO elevators do not 
allow researchers the cell type precision needed to draw such conclusions. One aim 
of this work is to develop a method that allows for cell-specific NO generation in order 
to investigate the role of NO in complex biological processes such as learning and 
memory at the level of specific cell types.  
This aim will be accomplished with transgenic mice and targeted NO generation, 
facilitated by cell type specific lacZ expression and a synthetic compound that releases 
NO upon cleavage by β-galactosidase. By placing the relevant gene (e.g. lacZ) under 
the control of a cell specific promoter with the Cre/loxP system, cell specific expression 
of lacZ, and thus β-galactosidase, is attainable. The NO-releasing compound 1-O-(1-
pyrrolidinyl-ONN-azoxy)-β-D-glucopyranose (β-gal-NONOate) is cleaved by the 
enzyme β-galactosidase at the anomeric carbon freeing the nitrogen salt NONOate 
from the sugar, after which the NONOate spontaneously degrades into two molecular 
equivalents of NO [141]. β-gal-NONOate is only cleaved in the presence of β-
galactosidase thus allowing for cell type specific generation of NO (Figure 7). One 
possible strategy is to use mouse lines with constitutive Cre expression, but this 
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creates potential problems with the animal's development and might result in complex 
phenotypes [137]. For this reason, we have used the Cre/loxP system and tamoxifen 
to induce time-specific gene modification when such mouse lines were available. 
Otherwise, we have employed mouse lines that have constitutive Cre expression. By 
combining this genetic manipulation strategy, the cGi500 biosensor, real-time 
microscopy, and traditional biochemical methods it is possible to investigate the NO-
cGMP signaling in a cell specific manner. Our strategy is to apply -gal-NONOate in a 
mouse line that has cell type specific lacZ and cGi500 expression. This would enable 
NO generation and cGMP visualization in only those cell types. Downstream 
physiological effects influenced by the addition of-gal-NONOate could also be 
investigated via real-time microscopy, such as vasodilation (Figure 7). 
 
Figure 7. Cell-specific elevation of NO with -gal-NONOate.  
NO can be elevated in a cell specific manner via the addition of -gal-NONOate, which releases NO in 
the presence of -galactosidase. By using the Cre/loxP system under a cell type specific promotor, cell-
specific lacZ, and thus-galactosidase, expression is possible. The cGi500 sensor can be used to 
visualize any changes in [cGMP]i upon the addition of -gal-NONOate. Physiological effects can be 
investigated via advanced methods, such as real-time microscopy to measure vasodilation. 
 
It is our aim to further elucidate NO-cGMP signaling in the CNS and other 
biological systems and the work presented here is a large step in exactly that direction. 
We believe this new method that allows for cell type specific NO generation provides 
the scientific community with a method to illuminate the role NO plays in specific cell 
types during modulation of physiological processes. 
Introduction 
 
20  
1.10 Aim of the work  
The role of cGMP in numerous physiological processes is well documented and 
with the development of cGMP-modulating medications for human use there is no 
doubt about the molecule’s biological significance. Together with other signaling 
molecules, such as Ca2+, cGMP serves as a crucial molecule in the nervous system, 
however the minutia of the signal transduction cascades involved need to be further 
elucidated. Given the great success that cGMP-modulating molecules have seen in the 
cardiovascular system (Table 1) there is high potential for cGMP-modulating 
medications for CNS diseases.  
The major objective of this thesis was to further investigate NO-cGMP signaling 
in the nervous system. With simultaneous real-time imaging of Ca2+ and cGMP 
signaling, we have studied a crosstalk between these two signaling pathways and 
further described the molecular pathway in CGNs. Furthermore, we sought to develop 
a new strategy based on the use of the Cre/loxP site-specific recombination system 
and the compound -gal-NONOate that enables cell type specific NO generation, thus 
facilitating greater spatiotemporal resolution when investigating NO-cGMP signaling 
(Figure 7). The cell type specific generation of NO would allow researchers to 
investigate previously difficult address subjects, for example, the role of neuron 
generated NO on vasodilation, or so-called neurovascular coupling. The -gal-
NONOate strategy would enable scientists to gain in vivo evidence for a long-
hypothesized, yet poorly investigated scientific idea, namely that neurons release 
vasoactive messengers (e.g. NO), which act directly on the vasculature to a cause a 
region-specific increase in blood flow. This new methodology can help delineate a 
signaling cascade from the molecular level up to the behavioral level. While this work 
focused primarily on the nervous system, the new method could be applied to any cell 
type of interest and biological process by using the appropriate cell type specific Cre 
expressing mice. To our knowledge, this is the first reported method that allows for the 
spatiotemporal controlled, cell type specific generation of NO. 
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2 Materials and Methods 
 
2.1 General materials 
2.1.1 Common compounds, reagents and antibodies 
 
0.4% Trypan blue Life Technologies 
10×Trypsin/EDTA Life Technologies 
100×Penicillin/Streptomycin (Pen/Strep) Life Technologies 
2-propanol Carl Roth 
30 mm glass coverslips VWR 
37% Hydrochloric acid (HCl) Carl Roth 
8-Br-cGMP  Biolog 
8-pCPT-cGMP Biolog 
Agarose Biozym Biotech 
ANP Tocris 
-gal-NONOate Self-synthesized 
Boric acid Carl Roth 
Bovine serum albumin (BSA) Carl Roth 
Chloroform/isoamyl alcohol Carl Roth 
CNP Tocris 
DEA/NO Axxora 
D-Glucose Carl Roth 
DMEM GlutamaxTM Life Technologies 
Dimethyl sulfoxide (DMSO) Carl Roth 
Diethylether Carl Roth 
EHNA Axxora 
Ethanol Carl Roth 
Fetal Bovine Serum (FBS) Life Technologies 
Glutamate Sigma 
Glutamine Life Technologies 
Hoechst 33258 Sigma-Aldrich 
IBMX Sigma 
Milrinone Sigma 
Paraformaldehyde (PFA) Carl Roth 
Phenol/chloroform/isoamyl alcohol Carl Roth 
Sildenafil Cayman 
Vinpocetine Cayman 
Zaprinast Santa Cruz 
Antibodies 
 
Alexa 488, Goat anti-mouse Cell Signaling, A-11029, 
Mouse anti-mouse -III-Tubulin Cell Signaling, 4466 
Rabbit polyclonal anti-cGKI  Customized [142] 
Rabbit polyclonal anti-cGKII  Customized [143] 
Rabbit monoclonal anti-GAPDH Cell Signaling, 2118 
Rabbit polyclonal anti--actin Abcam, 8227 
Hoechst  Sigma, 33258 
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2.1.2. Common buffers and solutions  
0.5 M EDTA pH 8.0 
Dissolve 186.1 g disodium ethylenediaminetetraacetic acid dihydrate (Na2EDTA·2 H2O) in 800 
mL H2O, add NaOH pellets until the solution reaches pH 8.0 and EDTA is dissolved. Adjust 
volume to 1 L. Autoclave and store at room temperature (rt). 
 
1× Trypsin/EDTA 
10×Trypsin/ETDA (0.5% / 0.2%, Life Technologies) 3 mL, add 27 mL PBS, store at 4 °C. 
 
10× TE pH 8.0 
100 mM Tris-Cl (100 mL/L 1 M Tris-Cl pH 8.0), 10 mM EDTA (20 mL/L 0.5 M EDTA, pH 8.0), 
autoclave and store at rt. 
 
10× RT buffer 
10×RT-buffer (pH 8.0) contains 500 mM KCl, 100 mM Tris, 15 mM MgCl2 and 2 mM dNTP- 
mixture. Store at −20°C. 
 
10× Reaction buffer S 
10×Reaction buffer S (Bioron) contains 100 mM Tris-HCl pH 8.8, 500 mM KCl, 0.1% Tween- 
20, 15 mM MgCl2, store at −20°C. 
 
1000× Hoechst 33258 
Dissolve Hoechst 33258 (Sigma-Aldrich) at 1 mg/mL in H2O, store 1 mL aliquots at −20°C. 
 
1 kb ladder DNA marker 
Add 250 μL 1 kb ladder (Life Technologies) to 8.25 mL 1×DNA loading dye, store 500 μL 
aliquots at 4°C. 
 
1 M Tris-HCl pH 6.8/7.4/8.0 
Dissolve 121.14 g tris(hydroxymethyl)aminomethane (Tris) in 1 L H2O, adjust pH to 6.8/7.4/8.0 
with concentrated HCl. Autoclave and store at rt. 
 
20% SDS 
Dissolve 200 g sodium dodecyl sulfate (SDS) in 1 L H2O at 60°C in a water bath. Store at rt. 
 
5× TBE 
Make 450 mM Tris-borate, 10 mM EDTA by weighing 54 g Tris and 27.5 g boric acid and 
dissolving both in approximately 900 mL H2O. Add 20 mL of 0.5 M EDTA (pH 8.0) and adjust 
the solution to a final volume of 1 L. Store at rt. 
 
5 M NaCl 
Dissolve 292.2 g NaCl in 1 L H2O. Autoclave and store at rt. 
 
6× DNA loading dye 
30% glycerol, 10% 10×TE, 0.05% bromophenol blue, 0.05% xylene cyanol. Store at 4 °C. 
 
70% Ethanol 
Mix 70 mL ethanol and 30 mL H2O 
 
Proteinase K 
Prepare 50 mg/mL proteinase K in 1×TE, store at −20°C. 
 
PBS Buffer 
NaCl (135 mM), KCl (3 mM), Na2HPO4·2H2O (8 mM), KH2PO4 (2 mM), in 10 L H2O. Adjust pH to 
7.4 and autoclave. 
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2.2. Mice 
All mouse lines were housed in the animal facility of the Interfaculty Institute of 
Biochemestry at the Eberhard-Karls University of Tübingen, Germany or the 
Neuroscience Department at the University of California San Diego (UCSD). 
Experiments at UCSD were performed according to protocols that are in strict 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health and in accordance with the guidelines 
established by the UCSD Institutional Animal Care and Use Committee (IACUC). All 
animal procedures were performed in compliance with the humane care and use of 
laboratory animals and approved by the local authorities. 
Mice were housed at 22 °C and 50–60% humidity in a 12 h light/12 h dark cycle with 
permanent access to standard rodent chow (Altromin Spezialfutter GmbH & Co. KG, 
Lage, Germany and Sniff Spezialdiaten GmbH, Soest, Germany) and tap water. Type 
II cages (360 cm2) were used for housing of single animals or groups with a maximal 
size of 2 – 3 animals. Type III (810 cm2) were used for groups of maximum eight 
animals. The bedding of a cage consists of autoclaved shredded wood chips (Tapvei). 
Wooden tunnels and tissues were provided (Tapvei) for environmental enrichment. 
The animal care takers changed the water and put the mice into clean cages weekly. 
For breeding, one or two female mice were housed together with one male mice in a 
Type II cage. The breeding period lasts for a maximum of twenty days. To prevent 
uncontrolled breeding, female mice were separated into a Type III cage before they 
gave birth. The pregnant animals were given access to breeding chow (Altromin and 
Sniff). The newborn animals were separated from their mothers and housed in cages 
with all female or all male littermates at 21 days of age. During the separation process 
animals were ear tagged and the tissues are used for subsequent genotyping. 
The following mouse lines were used: R26-CAG-cGi500(L1) [118], R26-CAG-
mT/cGi500(L2) [118], NO-GC KO of the 1 subunit [144], L7-Cre [145], Wnt1-Cre 
[146], SM-CreERT2 [147], Camk2-CreBAC [148], and R26-lacZ [149]. The R26-CAG-
cGi500(L1) (R26-cGi500-L1) mice express the cGMP sensor cGi500 in all cells and 
R26-CAG-mT/cGi500(L2) (R26-cGi500-L2) mice express membrane-targeted 
tandem-dimer tomato red fluorescent protein (mT) before Cre recombination and 
contain the L2 allele, where “L2” stands for “two loxP sites”. The R26-cGi500-L2 
recombines in a cell type specific manner after breeding with appropriate Cre mice. 
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Both mouse lines contain the strong chicken actin/β-globin (CAG) promoter to 
enhance biosensor expression [150]. 
 
Genotyping of the animals was performed by PCR analysis of ear puncture DNA using 
the following primers: for detection of the R26-cGi500-L1 and R26-cGi500-L2 allele, 
BB01, BB02 and BB03, which amplify a330-bp fragment of the wild type allele (BB01 
and BB02) and a 250-bp fragment of the transgene (BB01 and BB03); for NO-GC KO 
mice, BB19, BB20 and BB21, which amplify a 680-bp fragment of the wild type allele 
(BB19 and BB20) and a 830-bp fragment of the knockout allele (BB19 and BB21); for 
Cre allele (L7-Cre and Wnt1-Cre), Cre800 and Cre1200, which amplify a 402-bp 
fragment of the Cre transgene; for the Camk2-CreBAC allele, Camk1, Camk2, and 
Camk5, amplify a 300-bp fragment of the wild type allele and a 350-bp fragment of the 
transgene; for R26-lacZ allele, BB01, BB02 and RF 127, which amplify a 330-bp 
fragment of the wild type allele (BB01 and BB02) and a 210-bp fragment of the 
transgene (BB01 and RF127). Detailed information on genotyping protocols can be 
found in the appendix (Tables A1 and A2). Andreas Friebe (Institute of Physiology, 
Julius-Maximilians-University) developed the NO-GC KO mouse lines [144]. Hannes 
Schmidt (Interfaculty Institute of Biochemistry, University of Tübingen) provided the 
Camk2-CreBAC mice [148] that were orignally developed by Günther Schütz 
(German Cancer Research Center, Heidelberg University).  
 
2.3 Mouse genotyping 
Polymerase chain reaction (PCR) was performed to genotype the mice. The 
template DNA has to be extracted from the ear punches of the 21-day old mice. 
1 Place each ear punch into 50 µL PCR lysis buffer and incubate over night at 55°C. 
2 After overnight incubation vortex the sample to dissolve the ear punch completely. 
3 Centrifuge the sample at 15200 rcf for 5 minutes. 
4 Transfer the supernatant into a 0.5 mL PCR tube. 
5 Denature the DNA and inactivate the Proteinase K at 95°C for 15 minutes. 
6 Store the DNA containing solution at -20°C or use 1–3 µL of this sample (depending on 
the PCR) immediately for genotyping PCR. 
 
Materials 
 Proteinase K (Genaxxon): 50 mg/mL proteinase K in 1x TE buffer, store at -20°C 
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 10x Reaction buffer S (Bioron), store at -20°C 
 PCR lysis buffer – 10x reaction buffer S (5 L), proteinase K (1L), H2O to 50L, 
store at -20°C 
 
Every genotyping PCR has specific conditions depending on the respective annealing 
temperature of the primer set and the expected PCR Product length (Table A2). The master 
mix was prepared as shown below (Table 2). 
 
1. Pipette 2 µL genomic DNA into a new PCR tube. 
2. Prepare the appropriate volume of the master mix. 
3. Add 23 µL of the master mix to your DNA sample and pipette up and down. 
4. Prepare a positive control from an already genotyped DNA sample and a negative 
control with a negative DNA sample and a H2O negative control. 
5. Transfer the samples into the thermocycler (PEQLAB Peqstar 2x; PEQLAB Primus 96 
Advanced) and run the respective program. 
6. After the PCR is complete add 5 µL of 6x DNA loading dye to the samples. 
7. Run the PCR products (12 µL) with a 1 kb plus ladder (7 µL) on a Midori Green 
containing (2 µL per 50 mL agarose gel) 2% agarose gel. 
  
Table 2. PCR master mix (one reaction) 
DNA 
10x RT buffer 
Primer 1 
Primer 2 
Primer 3 
Taq Polymerase  
H2O 
Total volume 
2.0 µL 
2.5 µL 
0.3 µL 
0.3 µL 
0.3 µL 
0.3 µL 
19.3 µL 
25 µL 
 
 dNTP stocks: 100 mM dATP, 100 mM dCPT, 100 mM dGTP, 100 mM dTTP 
(Genaxxon), store at -20°C 
 10x RT buffer: 100 mM Tris-HCl pH 8.0, 500 mM KCl, 15 mM MgCl2, 2 mM of each 
dNTP (dATP, dCPT, dGTP, dTTP), in H2O, store at -20°C 
 Primer (Table A1): 25 pmol/µL (Eurofins Genomics) in H2O, store at -20°C 
 Taq Polymerase (Bioron), store at -20°C 
 Molecular size marker: Dilute 250 µL 1kb plus ladder (Life Technologies) in 8.25 mL 
1x DNA loading dye. Prepare aliquots with a volume of 500 µL and store one aliquot 
ready to use at 4°C while the others are stored at -20°C 
 Midori Green (nucleic acid staining solution, Nippon Genetics), store at 4°C 
 6x DNA loading dye: Glycerol 30%, 10x TE buffer 10%, bromphenol blue 0.05 %, 
Xylene cyanol 0.05%, store at 4°C 
 1x TBE buffer: Dillute 2 L of 5x TBE buffer with 8 L H2O, store at rt 
 LE Agarose (Biozym), store at rt 
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 2% agarose gel: Weigh 1 g LE agarose (Biozym) into 50 mL 1x TBE buffer. Put it into 
the microwave and heat it until the agarose is completely dissolved. Let it cool down 
(The outside of the Erlenmeyer flask should be a temperature that you can touch 
without pain) and add 2 µL of Midori Green (Nippon Genetics). Mix in the Midori Green 
with a magnetic stirrer and then poor the agarose gel into a chamber to let polymerize. 
 
 
2.4. Cell culture  
2.4.1. Primary culture of vascular smooth muscle cells 
Jacek Dobrowinski (Interfaculty Institute of Biochemistry, University of Tübingen) 
helped clean the isolated aortae. Primary VSMCs were isolated from the thoracic 
aortae of mice aged 6-12 weeks as previously reported [122]. Approximately 150,000 
VSMCs per aorta were isolated. Cells were grown in culture medium at 37 °C and 5% 
CO2. Primary VSMCs started to grow and spread after 24-48 hours and were generally 
confluent about five days after isolation. Petri dishes (100 mm) with PBS and a 33 mm 
dish with Ca2+-free medium (85 mM L-glutamate, 60 mM NaCl, 10 mM HEPES, 5.6 
mM KCl, 1 mM MgCl2, adjust pH to 7.4 with HCl, autoclave and store at 4 °C) were 
put on ice. Animals were sacrificed with CO2 or diethyl ether inhalation. The fur was 
made damp with 70% ethanol and the abdominal and thoracic cavity were opened 
with an incision beginning at the pelvis and ascending to the throat. The diaphragm, 
remaining intestines, esophagus and liver as well spleen and lung were removed. The 
heart was carefully lifted out of the body cavity to reveal the aorta. Then the aorta was 
removed by carefully cutting along the spine to free the aorta down towards the pelvis 
area. The aorta was transferred with the still attached heart into the petri dish with PBS 
on ice. Using two forceps, the heart was removed from the aorta. Under a 
stereomicroscope (Stemi 2000C), the surrounding fat tissue was carefully removed 
from the aorta. The aorta was then transferred into the 35 mm dish with Ca2+-free 
medium. It is especially important to place this dish on ice to delay degradation during 
the isolation of tissues from multiple animals. The cleaned, isolated aorta was then cut 
into ~3 mm length pieces.  
The following steps were performed under sterile conditions in a laminar flow 
hood. The aorta pieces were transferred into a 15 mL tube with enzyme solution A 
(e.g. 0.5 mL solution for 2 aortae) and incubated for 60 minutes in a 37°C water bath 
with gentle mixing every 10 minutes (the mixing will reduce time for the critical 
incubation in solution B and thereby increase viable cell yield). The 15 mL tube was 
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then centrifuge at 150 rcf for 3 minutes. The supernatant was carefully discarded via 
aspiration and the tissue pellet was suspended in enzyme solution B (same volume 
as for enzyme solution A). The sample was then incubated for a maximum of 12 
minutes at 37°C in a water bath. After the first 3 minutes of incubation a 1000 µL 
pipette was used to pipet the mixture up and down to assist tissue dissociation. This 
step is critical and should be performed as quickly as possible. The reaction was 
quenched with FCS containing culture medium using 3-4 times the volume of enzyme 
solution B. The solution was centrifuged at 140 rcf for 8 minutes. The supernatant was 
discarded via aspiration and the pellet suspended in an appropriate volume of medium 
(~0.5 mL per 2 aortae). 18 mL of the solution was combined with 2 mL of Trypan blue 
solution and pipetted into a Neubauer counting chamber to determine the number of 
viable and dead cells (blue positive). VSMCs were then plated according to the 
experimental requirements and grown at 37°C and 6% CO2. Medium was changed as 
necessary (about every 3 days). Cells were serum‐starved in culture medium without 
serum for 24 h prior to imaging experiments or protein isolation.  
Materials for primary VSMC isolation: 
 Ca2+-free medium (pH 7.4): 85 mM L-glutamate, 60 mM NaCl, 10 mM HEPES, 5.6 mM KCl, 1 
mM MgCl2, adjust pH to 7.4 with HCl, autoclave and store at 4°C 
 VSMC culture medium: 500 mL DMEM medium -GlutaMAXTM (Gibco) including 50 mL FCS and 
5 mL Pen/Strep, store at 4°C 
 10 mg/mL Collagenase: Dissolve 100 mg Collagenase (Sigma-Aldrich) in 10 mL Ca2+-free 
medium, prepare 0.5 mL aliquots and store at -20°C 
 10 mg/mL Hyaluronidase: Dissolve 100 mg Hyaluronidase (Sigma-Aldrich) in 10 mL Ca2+-free 
medium, prepare 0.5 mL aliquots and store at -20°C 
 7 mg/mL Papain: Dissolve 100 mg Papain (Sigma-Aldrich) in 14.29 mL Ca2+-free medium, 
prepare 0.5 mL aliquots and store at -20°C 
 100 mg/mL BSA: Dissolve 0.5 g BSA (Roth) in 5 mL Ca2+-free medium, sterilize by filtration, 
prepare 0.5 mL aliquots and store at -20°C 
 100 mg/mL DTT: Dissolve 0.5 g DTT (Roth) in 5 mL Ca2+-free medium, sterilize by filtration, 
prepare 0.5 mL aliquots and store at -20°C 
 Enzyme solution A (0.5 mL per 2 aortae): Dilute Papain stock 1/10, BSA stock 1/100 and DTT 
stock 1/100 in Ca2+-free medium 
 Enzyme solution B (0.5 mL per 2 aortae): Dilute Collagenase stock 1/10, Hyaluronidase stock 
1/10 and BSA stock 1/100 in Ca2+-free medium 
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2.4.2. Primary culture of cerebellar granule neurons 
To establish primary cultures of cerebellar granule neurons (CGNs) from mice, the 
following solutions and “tubes” were prepared: 0.3% bovine serum albumin (BSA, 
Roth) solution in 1× Krebs buffer, 14.3 mM D-glucose, 2.5 mM MgSO4, sterilized by 
filtration; “tube 1” contained 30 mL 0.3% BSA solution; “tube 2” contained 30 mL 0.3% 
BSA solution and 300 μL trypsin solution [2.5x trypsin-EDTA (Thermo Scientific) in 
PBS], added shortly before use; “tube 3” contained 7.8 mg trypsin inhibitor (Life 
Technologies) in 15 mL 0.3% BSA solution, 3.1 mM MgSO4, and 0.1 mg/mL DNase 
(Roche), added shortly before use); in “tube 4”, 17 mL 0.3% BSA solution were mixed 
with 8 mL solution from “tube 3” and then 10 mL were discarded, so that 15 mL 
remained in “tube 4”; “tube 5” contained 12.5 mL 0.3% BSA solution, 2.5 mM MgSO4, 
and 0.1 mM CaCl2. Two to five cerebella from 7-day-old mice were isolated and the 
surrounding meninges were removed in 0.3 % BSA solution. Then, the cerebella were 
homogenized in 2 mL 0.3% BSA solution with a pipette, transferred into “tube 1” and 
centrifuged at 170 g for 5 min at room temperature. The supernatant was removed 
and the pellet was resuspended in the solution from “tube 2” and incubated for 15 min 
at 37 °C with gentle shaking every 5 min. Then, the suspension was transferred into 
“tube 4”, mixed and centrifuged at 170 g for 5 min at room temperature. The 
supernatant was removed and the cell pellet was resuspended in the solution from 
“tube 3” by pipetting 10 times with a Pasteur pipette. Then, the suspension was 
transferred into “tube 5”, mixed, passed through a netwell mesh (70 µm), and 
centrifuged at 170 g for 5 min at room temperature. The pellet was resuspended in 
CGN medium [Minimal Essential Medium (Life Technologies) containing 0.22 mM KCl, 
2% B27 supplement (Thermo Scientific), 9% fetal bovine serum (Thermo Scientific), 
0.3 mM glutamine (Thermo Scientific), and 0.1 mM gentamicin (Thermo Scientific)] 
and plated on 24-well plates (100 k cells per well, viability >95% as determined by 
trypan blue staining). Wells were equipped with glass coverslips, which had been 
coated overnight with poly-D-lysine (20 µg/mL, Thermo Scientific). CGNs were grown 
at 37 °C and 5% CO2 and after 24 h cytosine arabinoside (5 µM, Sigma) was added. 
Every 3 days half of the medium was changed. 
 
Materials for primary CGN isolation: 
 10× Krebs buffer: 1.24 M NaCl, 54 mM KCl, 5 mM NaH2PO4, pH 7.4, autoclave and store at  
4 °C. 
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 1 M D-glucose: 19.8 g D-glucose · H2O in 100 mL H2O, sterilize by filtration, store at 4 °C. 
 1.2% CaCl2: 1.2 g CaCl2 · 2H2O in 100 mL H2O, sterilize by filtration, store at 4 °C. 
 3.82% MgSO4: 3.82 g MgSO4 · 7H2O in 100 mL H2O, sterilize by filtration, store at 4 °C. 
 0.3% BSA solution (prepare always fresh on the day of use): 450 mg BSA into a beaker glass, 
132.84 mL H2O, 15 mL 10×Krebs buffer, 2.16 mL 1 M D-glucose and 1.2 mL 3.82% MgSO4. 
Adjust the pH to 7.4 with NaOH, sterilize by filtration, store at 4 °C. 
 50 mg/mL Gentamicin (GIBCO, Life Technologies). 
 High K+ (HK) medium: 825 mg KCl in an autoclaved beaker glass, 50 mL MEM, sterilize by 
filtration and transfer it back into the original medium bottle (total volume 500 mL MEM). Add 1 
mL of gentamicin (50 mg/mL), store at 4 °C. 
 CGN medium: 88 mL HK medium, 9 mL FBS, 0.9 mL 100×L-glutamine, 2 mL 50× B27 
supplement, store at 4 °C for up to 1 month. 
On the day of preparation (postnatal day 7), prepare 5 × 50 mL centrifuge tubes in the 
tissue culture hood:  
Tube 1: 30 mL 0.3% BSA solution.  
Tube 2: 30 mL 0.3% BSA solution and, shortly before use add 300 μL 2.5% trypsin.  
Tube 3: Dissolve 7.8 mg trypsin inhibitor in 15 mL 0.3% BSA solution (thorough mixing and warming to 
37°C facilitates its dissolution), add 150 μL 3.82% MgSO4, and shortly before use add 150 μL 1% 
DNase.  
Tube 4: 17 mL 0.3% BSA solution and 8 mL from tube 3; discard 10 mL, so that 15 mL remain in the 
tube.  
Tube 5: 12.5 mL 0.3% BSA solution, 100 μL 3.82% MgSO4 and 15 μL 1.2% CaCl2.  
Distribute part of the remaining 0.3% BSA solution into 10 × 35 mm culture dishes (~3 mL/dish); keep 
on ice for preparation of the brains. 
 
2.5. Transfection of primary VSMCs 
Isolated primary VSMCs were transfected with the lacZ encoding plasmid 
pFRT-gal (Figure A1). Cells had a confluence of 80% or higher upon transfection. 
Here the lipofection method was used to transfect the construct pFRTβ-gal into 
VSMCs grown in 6-well plates. The cell medium was aspirated and pre-warmed (37 
°C) VSMC culture medium was added (1.25 mL per 6-well). The transfection mixtures 
of ScreenFect A Transfection kit (Genaxxon Bioscience) were prepared fresh. Tube A 
contained 120 μL of dilution buffer with 6 μL ScreenFect A. Tube B contained 120 μL 
dilution buffer with 1 μg plasmid DNA. ‘Tube A’ was added to ‘tube B’ and pipetted up 
and down to mix them well and then incubated for 20-30 min at rt. Thereafter, 240 μL 
of the transfection mixture were added per well in a 6-well plate on top of the 1.25 mL 
VSMC culture medium. There might be a color change in the medium of the cells. The 
cells were incubated overnight at 37 °C and 5% CO2. 15-20 h after the transfection, 
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the medium was replaced with VSMC culture medium. (Do not wash with PBS). The 
cells were analyzed two days after transfection.  
 
Materials: 
 VSMC culture medium: 500 mL DMEM medium -GlutaMAXTM (Gibco) including 50 mL FCS and 
5 mL Pen/Strep, store at 4°C. 
 
2.6. Preparation of acute brain slices and fixed brain sections 
For the preparation of acute brain slices, brains were dissected and cut in ice-cold 
carbogen-gassed Ringer buffer (126 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 
1.25 mM NaH2PO4, 26 mM NaHCO3, 20 mM D-glucose). Slicing was performed with 
a vibratome (VT1200, Leica, BuffaloGrove, IL, USA). Brains were cut sagittally into 
300-m slices. Then, slices were incubated in 37 °C pre-warmed carbogen-gassed 
Ringer buffer and imaging experiments were performed 45-60 min after slicing. 
 
2.7. Animal procedures for imaging under anaesthesia  
2.7.1. Surgical implantation of mouse cranial window 
Surgeries were performed by Martin Thunemann and Qun Cheng (Department of 
Neurosciences, University of California, San Diego). Experiments performed 
according to these protocols were in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health. The experiments at the University of California San Diego were all performed 
in accordance with the guidelines established by the UCSD Institutional Animal Care 
and Use Committee (IACUC). Surgeries were performed as described in this section 
and as previously described [151]. We used adult female mice on a C57BL/6 
background. Surgical installation of the cortical window was performed while the mice 
were anesthetized with isoflurane (2% initially, 0.5–1% during all procedures). A 
cannula was inserted into the femoral artery. A metal holding bar was glued to the 
temporal bone for immobilization of the head during imaging. An area of skull overlying 
the Barrel cortex region contralateral to the holding bar was exposed and dura mater 
removed. A ~2 × 2 mm cranial window was centered on the Barrel cortex region’s 
stereotactic coordinates: antero-posterior coordinates −1.5, medial-lateral coordinates 
2. Cold ACSF (142 mM NaCl, 5 mM KCl, 10 mM glucose, 10 mM HEPES, 3.1 mM 
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CaCl2, 1.3 mM MgCl2, pH 7.4) was used during surgery to keep the skull cool during 
drilling. A drop of agarose (1% wt/vol, A9793, Sigma) in ACSF was applied on the 
brain surface, and the exposure was covered with a round glass coverslip (5 mm, 
WPI). To avoid herniation of the exposed brain due to excessive intracranial pressure, 
the dura mater over the 4th cerebral ventricle was punctured, thus allowing drainage 
of CSF. After the exposure was closed, the drainage hole was sealed with agarose. 
To allow for the addition of pharmacological agents directly into the brain, the 
round glass coverslip was cut straight on one side facing a gap in the dental acrylic 
seal. The agar was cut down along the cut side forming a vertical wall. The exposure 
was aligned with the agar wall such that ACSF under the objective was in direct contact 
with the cortical surface allowing drugs to penetrate into the cortical tissue. 
After closing of the exposure, mice were left to rest under 1% isoflurane for 45 min. 
Waiting for 45 min between closing the exposure and drug injections minimizes 
leakage of the drugs onto the cortical tissue exposed through the cut dural blood 
vessels. Isoflurane was then discontinued and further anesthesia was maintained with 
α-chloralose (50 mg/kg/h IV, C0128, Sigma or 100459, MP Biochemicals). Mice were 
paralyzed with pancuronium bromide (0.4 mg/kg/h IV, P1918, Sigma) [152] and 
ventilated (~110 min-1) with 30% O2 in air. Fluorescein isothiocyanate (FITC)-labeled 
dextran (MW = 2 MDa, FD-2000S, Sigma) was retro-orbitally injected (50–100 μl of 
5% (w/v) solution in phosphate-buffered saline) to visualize the vasculature and control 
for the integrity of the capillary bed. Expired CO2 was measured continuously using a 
micro-capnometer (Cl240, Columbus instruments). Heart rate, blood pressure, and 
body temperature were monitored continuously. Blood gas was analyzed to cross-
validate the micro-capnometer measurements. Respiration was adjusted to achieve 
PaCO2 between 30 and 40 mmHg and pH between 7.35 and 7.45. α-chloralose and 
pancuronium in 5% dextrose saline were supplied through the femoral line every 
30 min for the duration of data acquisition. 
2.7.2.  Microinjection protocol and mouse monitoring 
The microinjection pipette was guided under the glass coverslip and positioned ~ 
200 μm below the cortical surface using a Luigs & Neumann translation stage (380FM-
U) and manipulation equipment integrated into the Ultima system. The red fluorescent 
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dye Alexa 594 (A-10442, Alexa Fluor 594 hydrazide, sodium salt, Invitrogen) was 
added to the solution in order to visualize the micropipette during manipulation and to 
provide visual feedback during pressure-microinjection into the cortical tissue [153]. 
The injection pressure was manually adjusted to ensure visible spread of Alexa 594 
while avoiding movement artifacts. The injection occurred locally with a volume 
between 5-10 L depending on the diameter of the quartz needle, the duration of 
injection, and the pressure during injection. A video camera (Lifecam Studio, Microsoft; 
IR filter removed) with an NIR longpass filter (Midwest Optical LP920-25.5) was used 
for continuous observation of the mouse during measurement. The IR illumination 
(M940L3 - IR (940 nm) LED, Thorlabs) was invisible to the PMT photodetectors and 
does not generate imaging artifacts. The camera frames were synchronized with two-
photon imaging and recorded. Periods with extensive body movement (e.g., grooming 
behavior) were excluded during data analysis. Analysis was performed as a pseudo 
line scan in Fiji (NIH) [154] by measuring the diameter of the vessel across time. A line 
of interest was drawn followed by the command: Image  Stacks  Reslice which 
then generates a pseudo line scan “stack”. The resulting image is depicted as a series 
of slices, each a single-pixel in width along the line of interest. The total area analysis 
was performed in MATLAB. The analysis measured the total vessel area across time 
with a region of interest (ROI) that determined the percent area the vessel changes in 
the ROI over time.  
 
 
2.8. Microscopy imaging setups  
FRET/cGMP and Ca2+ imaging of cultured cells was performed as described here 
and previously [40,116,118,122,155].  
 
2.8.1. Fluorescence microscopy on Axiovert 200 microscope 
A schematic representation of the setup is shown below (Figure 8). The setup 
consisted of an inverted Axiovert 200 microscope (Zeiss) equipped with a 
NeoFluar40x/1.30 oil objective, a light source with excitation filter switching device 
(Oligochrome, TILL Photonics GmbH), a Dual-View beam splitter (Photometrics) with 
516 nm dichroic mirror and emission filters for CFP (480/30 nm) and YFP (535/40 nm), 
and a charge-coupled device camera (Retiga 2000R; QImaging).  
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cGMP imaging was performed with VSMCs or CGNs isolated from R26-cGi500-
L1 mice expressing the cGi500 sensor. For simultaneous imaging of cGMP and Ca2+, 
coverslips with cGMP sensor cells were incubated with 2.5 µM Fura-2AM 
(Calbiochem; 1 mM stock solution in DMSO) in Tyrode buffer (140 mM NaCl, 5 mM 
KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 5 mM D-glucose, 5 mM HEPES, pH 7.4) for 35 
min at 37 °C in the dark before measurement. During cGMP only measurements, 
coverslips were briefly washed in Tyrode buffer to remove cell medium. All coverslips 
were mounted into a Warner Instrument SA-20LZ superfusion imaging chamber 
(Harvard Bioscience) and superfused at 37 °C at a flow rate of 1 mL/min with Tyrode 
buffer or Tyrode buffer supplemented with drugs. Test compounds were applied via 
Pharmacia IV-7 injection valves (GE Healthcare) with either 7.0 mL, 2.0 mL or 0.16 mL 
sample loops. CGNs were imaged at 40x magnification, VSMCs were imaged at 10x 
magnification, and both were imaged with 4x4 binning. Signals were recorded at a 
frequency of 5 Hz or 1 Hz for cGMP imaging alone or simultaneous cGMP/Ca2+ 
imaging, respectively. For Fura-2-based Ca2+ imaging in CGNs, fluorescence was 
excited at 340/26 nm and 387/11 nm (15% lamp intensity each) and emission was 
recorded in the 535/40 nm channel (65 ms and 20 ms exposure time with the 
respective excitation wavelength). For cGMP imaging with CGNs, excitation was 
performed at 445/20 nm (45% lamp intensity) and emission recorded simultaneously 
at 480/30 nm and 535/40 nm (40 ms exposure). For cGMP imaging with VSMCs, 
excitation was performed at 445/20 nm (100% lamp intensity) and emission was 
recorded simultaneously at 480/30 nm and 535/40 nm (300 ms exposure). 
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Figure 8. Schematic representation of the cGi500 FRET imaging system. 
A schematic representation of the above described imaging setup to measure cGMP with the cGi500 
FRET-based sensor. Adapted from [122]. 
 
2.8.2. Fluorescence microscopy with Examiner.Z1 spinning disc microscope  
The spinning disk microscope setup consisted of an upright Examiner.Z1 
microscope (Zeiss), a Yokogawa CSU-X1 spinning disk confocal scanner, three diode 
lasers (445 nm, 488 nm and 561 nm), three water immersion objectives [W N-
ACHROMAT 10x/0.3, W Plan-APOCHROMAT 20x/1.0 DIC (UV) VIS-IR, W Plan-
APOCHROMAT 40x/1.0 DIC VIS-IR; all from Zeiss] and one air objective [EC Plan-
NEOFLUAR 2.5x/0.085; Zeiss]. For FRET-based cGMP imaging, the donor 
fluorophore CFP was excited with the 445 nm laser, and a Dual-View beam splitter 
(Photometrics) with 505 nm dichroic mirror, and 470/24 nm and 535/30 nm emission 
filters was used for simultaneous acquisition of CFP and YFP. Signals were recorded 
with an electron-multiplying charged-coupled device (EM-CCD) camera (QuantEM 
512SC, Photometrics) at a frame rate of 0.2 Hz and an exposure time of 300 ms. The 
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system was controlled by VisiView software (Visitron Systems). A CoolLED pE-2 LED 
system was used for epifluorescence illumination at 400 nm, 450 nm, 500 nm, and 
561 nm. During real-time imaging, the tissue was continuously superfused with 
carbogen-gassed Ringer buffer (126 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 
1.25 mM NaH2PO4, 26 mM NaHCO3, 20 mM D-glucose) or Ringer buffer containing 
drugs of interest at a flow rate of 1 mL/min at 37 °C. A custom-built superfusion system 
was used consisting of a FPLC pump (Pharmacia P-500, GE Healthcare), FPLC 
injection valves (Pharmacia V-7, GE Healthcare), a magnetic platform (Warner 
instruments), a superfusion chamber (RC-26, Warner Instruments), a Slice Hold-Down 
(SHD-26H/10, Warner Instruments) and a sample loop (2 mL). To remove the buffer 
from the system, a vacuum pump with adjustable vacuum (Laboport N86, KNF 
Neuberger) was connected to the system [118,122]. 
 
2.8.3. Fluorescence microscopy with a 2-photon microscope  
Martin Thunemann (Department of Neurosciences, University of California, San 
Diego) assisted with data collection and analysis. Images were obtained using an 
Ultima 2-photon laser scanning microscopy system (Bruker Fluorescence Microscopy) 
equipped with an Ultra II femtosecond Ti:Sapphire laser (Coherent) tuned between 
800–1000 nm and cooled GaAsP PMT tube detectors (H7422P-40, Hamamatsu) and 
a multialkali PMT (R3896, Hamamatsu). The setup was equipped with two filters 
(ET480/40m, Chroma and T505lpxr, Chroma). Olympus 20x (XLUMPlanFLNXW, 
NA=1.0) and Zeiss 40x (IR-ACHROPLAN, NA = 0.8) water-immersion objectives were 
used for high-resolution imaging. In experiments involving manipulation of a 
micropipette under the coverslip, we used a combination of Zeiss 5x (Plan-
NEOFLUAR, NA=0.16) and Olympus 20x (UMPlanFI, NA=0.5) objectives for a coarse 
approach and fine manipulation under the glass coverslip, respectively. The laser 
beam diameter was adjusted to overfill the back aperture. Arteriolar diameter 
measurements were performed in a frame-scan mode at 10–20 Hz, or in a 'free-hand' 
line-scan mode with a scan rate of 25–50 Hz. The scan resolution was 0.5 μm or less.  
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2.9. Imaging protocols  
Below is the detailed work flow for the cGMP FRET measurement of cells expressing 
cGi500. This is true for both the Axiovert 200 microscope and Examiner.Z1 spinning 
disc microscope. 
 
Note: VSMCs were serum starved 24 hours before measurement. This procedure 
should better imitate the in vivo situation where VSMCs are mitotically inactive.  
1.  Before measurement, perform a solvent change (injection valves in load mode) 
with buffer and check the beam splitter for CFP and YFP alignment. Also ensure 
that the appropriate sample loops are assembled and that all other materials 
needed for the measurement are prepared (drugs, drug application sheets, 
pipettes etc.) 
2. Assemble the superfusion chamber with a coverslip: Use a paint brush to apply 
silicon to the chamber and ensure that the border of the chamber is free of 
silicon where the coverslip will be placed. The silicon may influence 
measurement quality. Place the coverslip in the chamber and cover the cells 
with buffer (gently pipet about 700 L onto the coverslip). If working with tissue 
slices, then use the harp to immobilize the tissue slice and ensure the chamber 
is full of buffer (about 1 mL). 
3. Clean the bottom side of the coverslip (where no cells should be) with a kimwipe 
and, if necessary, ethanol. 
4. Place the chamber on the microscope and connect it to the superfusion system, 
both in and out valves. 
5. Start the superfusion system with a rate of 60 mL/hour and ensure injection 
valves are in the load mode. Make sure that the buffer is correctly aspirated, 
just enough volume to ensure the cells or tissues are always wet. Large 
volumes tend to produce weaker signals. Ensure that the chamber is not leaky. 
6. Use the YFP filter set to identify a representative region of interest (ROI). 
Acquire a fine-grained image of this region (1x1 binning and ~2 sec exposure 
time). This image makes it easier to map the cells for analysis. 
7. Adjust the imaging settings as necessary for your specific measurement. 
8. Start the measurement and first record a stable baseline for about 3 min. This 
is important for the baseline correction used in the analysis. 
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9. For drug application, prepare the appropriate concentrations by diluting them in 
buffer. Then load the solution into the loop ensuring no air bubbles enter the 
system. Initiate drug release into the perfusion system by switching the injection 
valves from load into inject mode. Natriuretic peptides and glutamate are rather 
stable and dilutions can be prepared in large scale. DEA/NO is only stable in 
an alkaline environment, dilutions should be prepared shortly before 
administration. 
10. Observe FRET changes and wait until the baseline is reached before initiating 
the next drug administration. After the baseline is reached, flush Tyrode buffer 
through the sample loop to remove potential drug residues which could 
influence the next application. 
11. After completing the measurement clean the superfusion system by flushing it 
2x with 20% ethanol (run solvent change, injection valves once in load mode 
and once in injection mode). Remove the sample and any remaining silicon 
from the superfusion chamber. Clean up any spills. Save data ASAP to an 
external hard drive.  
 
2.10. PDE inhibitor experiments  
Stefanie Peters (Interfaculty Institute of Biochemistry, University of Tübingen) 
collected and analysed the data. cGMP measurements with various PDE inhibitors 
were performed on the Axiovert 200 microscope setup described previously. A 
baseline of 3 mins was collected. Then primary CGNs were stimulated for 2 min with 
DEA/NO (50 nM) alone and then superfused for 5 min with PDE inhibitor followed by 
2 min with DEA/NO (50 nM) and PDE inhibitor in combination, and a final 2-min 
stimulation with DEA/NO (50 nM) alone. All drug applications were performed after the 
preceding FRET signal had returned to baseline. 
 
2.11. Protein isolation and western blotting 
Andrea Schramm (Department of Pharmacology and Toxicology, University of 
Regensburg) performed some of the Western blots and analysis. Either tissues or 
CGNs in culture were treated with lysis buffer (0.67% SDS (w/v), 21 mM Tris/HCl (pH 
8.3), 0.2 mM phenylmethylsulfonylfluoride, and one tablet of PhosSTOP™ 
phosphatase inhibitor cocktail (Roche) per 10 mL). Protein concentrations of the 
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lysates were measured with the Total Protein Kit, Micro Lowry, Peterson’s modification 
(Sigma). Protein lysates were subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blot analysis on polyvinylidenefluoride 
membranes. Membranes were stained with the following antibodies: rabbit polyclonal 
anti-VASP (1:1000, Cell Signaling, 3112); rabbit polyclonal anti-cGKI (1:5000, [142]); 
rabbit monoclonal anti-GAPDH (1:1000, Cell Signaling, 2118); rabbit polyclonal anti-
cGKII (1:100, [143]); and rabbit polyclonal anti--actin (1:2000, Abcam, 8227). 
Antibody binding was detected using HRP-conjugated secondary antibodies (goat 
anti-rabbit IgG, 1:2000, Cell Signaling, 7074; or 1:7500, Dianova, 111-035-003) and a 
chemiluminescent substrate (Advansta WesternBright ECL, Biozym; or ClarityTM 
Western ECL Substrate, Bio-Rad Laboratories). Signals were recorded with a CCD 
camera (Alpha-Imager, Bio-Rad Laboratories; or ChemiDoc system, Bio-Rad 
Laboratories). Further analysis was performed with Fiji (NIH) [154] or ImageLab 
software (Bio-Rad Laboratories). Control tissues were obtained from 8- to 25-week-
old wild-type mice on a C57BL/6 or mixed C57BL/6 x 129/Sv genetic background. 
Tissues were dissected in PBS and then homogenized in lysis buffer using a FastPrep 
homogenizer (MP Biomedicals) or ultra-turrax (IKA).  
VASP phosphorylation can can be visualized via Western blot. VASP has three 
phosphorylation sites: Ser157, Ser239 and Thr278, which can be phosphorylated via 
interaction with cGKs or cAMP dependent protein kinases (cAKs). cAKs phosphorylate 
VASP preferentially at Ser157, whereas cGKs at Ser239. VASP and phosphorylated 
VASP at Ser157 migrate differently in a SDS/PAGE with unphosphorylated VASP at 
46 kDa and phosphorylated VASP at 50 kDa [156]. VASP-phosphorylation is used as 
a measurement of cAK or cGK activity and thus indirectly cGMP or cAMP levels.  
 
 
2.12. Detailed working protocol for Lowry, SDS-Page and Western blotting  
 
2.12.1. Lowry protein assay 
Protein extraction from cells 
1. Aspirate culture medium and wash the cells 2x with room temperature PBS. 
2. Add the appropriate volume of SDS lysis buffer (for example 1 well out of a 6 
well plate can be lysed with 100 µL but 2 wells can be pooled with 150 µL) and 
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lyse the cells by scratching the culture dish with a pipette tip. If possible, pool 
the wells to increase protein concentration. 
3. Tilt the culture dish and use a cell scratcher to pull the lysate to the bottom of 
the dish (this will increase the protein concentration). Store samples on ice. 
4. Denature cell lysates at 95°C for 10 minutes. 
5. Centrifuge for 5 min at 18,000 rcf and transfer the supernatant into a new tube. 
6. Store the samples at -20°C. 
Protein extraction from tissue 
1. Isolate the desired tissue and transfer it into an Eppendorf tube. 
2. Storage is possible by shock freezing the samples with liquid nitrogen and 
storing at -80°C. 
3. Alternatively, transfer the tissues into prepared lysis cups with a ceramic ball 
and a spatula of sand. 
4. Add SDS lysis buffer. The amount of lysis buffer depends on the tissue (Table 
3) but no less than 200 µL should be used. 
5. Place the tubes in the FastPrep homogenizer (MP Biomedicals) and run the 
device for 20 seconds at 6.5 M/s. 
6. Centrifuge the samples for 2 minutes at 10,600 rcf and check if they are lysed. 
If not add some additional lysis buffer and go back to step number six. 
7. Denature the lysates at 95°C for 10 minutes. 
8. Store at -20°C. 
 
Table 3. Recommended amount of SDS lysis buffer 
Tissue 
Brain, Liver, Colon 
Lunge 
Heart, Spleen, Kidney 
SDS lysis buffer (min. 200 µL) 
4 µL/mg 
9 µL/mg 
10 µL/mg 
 
 
Determination of protein concentration with Lowry assay 
To determine protein concentration, we used the Total Protein Kit from Sigma. This 
assay is based on the Peterson modification of the Lowry method. In a first reaction 
step, alkaline copper tartrate forms complexes with protein peptide bonds (Biuret 
reaction). In the second colorimetric reaction step, Folin-Ciocalteau is reduced by 
copper whereby a blue product is formed. The intensity of the color correlates with the 
protein concentration. The Lowry assay is performed within a 96 well plate and the 
samples are quantified by the Thermo Multiskan EX plate reader. A concentration 
series of bovine serum albumin (BSA) is used to generate the standard curve. 
1. Transfer 200 µL of each sample from the BSA standard series into a new 
Eppendorf tube. As a blank reference use 200 µL H2O. 
2. Pipette 15–30 µL of the protein lysate into a new Eppendorf tube and fill up to 
200 µL with H2O. As a second reference, use 15-30 µL lysis buffer filled to 200 
µL with H2O. 
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3. Add 200 µL Lowry Reagent Solution (total volume 400 µL), lightly vortex the 
sample and incubate for 20 minutes at rt. 
4. Add 100 µL Folin-Ciocalteau (total volume 500 µL), vortex the sample and 
incubate for 30 minutes at room temperature in the dark. This step is when the 
colorimetric reaction occurs. 
5. Transfer 200 µL of this reaction into a 96 well plate giving a total volume of 500 
µL. Prepare duplicates or triplicates for each sample. Remove air bubbles either 
with a lighter flame or carefully with a pipette. 
6. Read absorption at 620 nm with the Thermo Multiskan EX plate reader. 
7. Prepare a calibration curve of the BSA concentration series and use it to 
calculate the protein concentration of the samples. 
 
Materials: 
 Total Protein Kit (Sigma): This kit supplies the Lowry Reagent Solution and 
Folin-Ciocalteau. 
 Bovine serum albumin (BSA): Prepare a BSA (Roth) concentration series (200, 
100, 50, 25, 12.5 µg/mL) in H2O and store it at -20°C. 
 
2.12.2. SDS-Page and Western blotting  
To identify the expression of specific protein in target samples, the samples must 
first be separated according to their molecular weight by SDS-Page. Subsequent 
Western blot analysis is then performed where the proteins separated by SDS-Page 
are transferred to a PVDF (poly-vinylidenfluoride) membrane. Protein specific primary 
antibodies are used to bind the desired target and horseradish peroxidase (HRP) 
linked secondary antibodies are used to visualize the immobilized proteins on the 
PVDF membrane. For the detection of the secondary antibody we used a 
commercially available ECL (enhanced chemiluminescense) reagent which reacts 
with HRP under light emission and can be detected by a CCD-camera. 
Depending on the molecular weight from the protein of interest, SDS-gels with the 
appropriate percent acrylamide have been prepared (using Mini Protean 3 system 
from BioRad). For larger proteins (> 30 kDa), gels with lower acrylamide content (8%) 
were prepared (Table 4) and gels with greater acrylamide content were used for the 
separation of smaller proteins (< 30 kDa). Depending on the amount of protein loaded 
it was possible to choose between 0.75 mm or 1.5 mm thick gels. The standard gel 
used in this thesis was 1.5 mm thick and had an acrylamide content of 10%. The 10-
slot comb was used to produce ten wells. This allows one to load ~30 µL of protein 
sample without any problems.  
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Table 4. Composition of polyacrylamide gel 
Components Separating gel  
(1 gel 0.75 mm) 
Stacking gel  
(max. 3 gels 0.75 mm) 
  
8% 
 
10% 
 
12% 
 
4% 
Rotiophorese® 
4x Tris/SDS pH (8.8) 
4x Tris/SDS pH (6.8) 
H2O 
TEMED 
APS 
1.4 mL 
1.3 mL 
/// 
2.4 mL 
5 µL 
25 µL 
1.7 mL 
1.3 mL 
/// 
2.1 mL 
5 µL 
25 µL 
2 mL 
1.3 mL 
/// 
1.7 mL 
5 µL 
25 µL 
0.65 mL 
/// 
1.3 mL 
3.1 mL 
10 µL 
25 µL 
 
Note: Double the amount for the preparation of 1.5 mm thick gels. 
 
 
SDS gel preparation 
1. Clean spacer and glass plates with 70% ethanol. 
2. Assemble the glass plates in the BioRad system. 
3. Prepare the separating gel and pour it between the glass plates up to the lower 
edge of the green boarder. To get rid of bubbles, overlay the gel with a thin 
ethanol layer. The polymerization reaction takes about 20-30 minutes. 
4. Tilt the gel und use a paper towel to remove the ethanol. 
5. Prepare the stacking gel and pour it up to the top edge of the glass plates.  
6. Insert the comb and ensure no bubbles form in the solution. Allow 
polymerization to occur for about 20-30 minutes. 
7. If the gel is not used immediately then wrap it in a wet paper towel, pack it with 
fresh wrap and store at 4°C. 
 
Materials 
 4x Tris-Cl/SDS pH 8.8: Tris-Cl 1.5 M (182 g/L), SDS 0.4% (4 g/L), H2O to 1 L, 
adjust pH to 8.8 with HCl, store at 4°C 
 4x Tris-Cl/SDS pH 6.8: Tris-Cl 0.5 M (60.4 g/L), SDS 0.4% (4 g/L), H2O to 1 L, 
adjust pH to 6.8 with HCl, store at 4°C 
 10x SDS running buffer: Tris-Cl 0.25 M (30.2 g/L), Glycine 1.9 M (144 g/L), SDS 
0.1% (1 g/L), H2O to 1 L 
 5x SDS loading dye: Tris-Cl (3.2 mL/10 mL Tris-CL pH 6.8), Glycerol 40% (4 
mL/10mL), SDS 15% (1.5 g/10 mL), 2-mercaptoethanol 3.6 M (2.5 mL/10 mL), 
Bromphenol blue 0.1% (10 mg/10 mL), H2O to 10 mL, store 1 mL aliquots at -
20°C 
 20% APS: Dissolve 2 g ammonium persulfate (APS) in 10 mL H2O, prepare 1 
mL aliquots and store at -20°C 
 
 
Materials and Methods 
 
42  
SDS-Page and Western Blot analysis 
1. Pull out the comb from the SDS gel 
2. Carefully use deionized water to wash the gel pockets free of any remaining 
acrylamide. 
3. Place the gel into the running chamber. The short side has to be faced inward. 
4. Fill up the inner and outer part of the chamber with 1x SDS running buffer. 
5. Denature the protein sample (lysate in 1x SDS loading dye) for 10 minutes at 
95°C. 
6. Load the sample and 3 µL protein marker (PageRulerTM Plus Prestained Protein 
Ladder, Fermentas). 
7. Run the gel with 100 V until the stacking gel is passed and then apply up to 150 
V for the separating gel. 
8. In the meantime, prepare the Whatman filter papers (16 per gel) and PVDF 
membrane for Western blot analysis. 
9. Around 5 minutes before the SDS gel is ready immerse the Whatman papers 
in the proper buffers and rinse the PVDF membrane in methanol. This methanol 
procedure is crucial to “hydrate” the PVDF. Otherwise protein transfer and 
binding would be impaired. 
10. Assemble the Whatman papers, PVDF membrane and SDS gel in the semi dry 
blotting device (Roth). After every layer of filter papers use a plastic pipette and 
roll over the stack to remove potential air bubbles (Figure 9). 
 
Figure 9. How to set up the Western blot with Whatman papers.  
Image credit: Jacek Dobrowinski. 
 
11. Blot the membrane for 80 minutes with 55 mA per stack. In the meantime, 
prepare 5% and 1% milk powder in 1x Tris-buffered saline with Tween-20   
(TBS-T). 
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12. Cut the membrane and label it with a pencil. 
13. Block the membrane for 1 hour with 5% milk powder solution at rt. 
14. Wash the membrane 2x 3 min with 1x TBS-T. 
15. Put the membrane into the primary antibody and incubate it overnight at 4°C on 
a rolling shaker. Alternatively incubate for 2 hours at rt (This depends on the 
experience with the desired antibody). 
16. Wash the membrane 3x 3 minutes with 1% milk powder solution. In the 
meantime, prepare the HRP-linked secondary antibody (5 mL in a 50 mL Falcon 
tube are suitable). 
17.  Put the membrane into the secondary antibody and incubate it for at least 1 
hour at rt on a rolling shaker. 
It is recommended to seal the primary and secondary antibody tubes with Parafilm to 
prevent leaking. 
18.  Wash the membrane 1x 3 minutes in 1% milk powder and 2x 3 minutes in 1x 
TBS-T. 
19. Prepare undiluted or diluted (1:2 up to 1:10) ECL reagent by mixing solution A 
and solution B. For the preparation of the dilution us 1x TBS-T. Pipette the ECL 
reagent on the membrane and acquire chemiluminescence images after 
appropriate acquisition times (3 seconds up to 10 minutes). 
20. After developing the blot, also acquire a bright field image of the marker. 
21. The Western blot can be evaluated with ImageJ [157]. 
 
Materials 
 Anode buffer I (pH 10.4): Tris-Cl 0.3 M (36.3 g/L), Methanol 20% (200 mL/L), 
H2O to 1 L 
 Anode buffer II (pH 10.4): Tris-Cl 0.025 M (3.03 g/L), Methanol 20% (200 mL/L), 
H2O to 1 L 
 Cathode buffer (pH 7.6): Aminocaproic acid 0.04 M (5.2 g/L), Tris-Cl 0.025 M 
(3.03 g/L), Methanol 20% (200 mL/L), H2O to 1 L 
 1x TBS-T: 1x TBS (100 mL/L 10x TBS-T) with 0.1% Tween-20 (1 mL/L) 
 Milk powder solution: Dissolve 5 g (5%) or 1 g (1%) milk powder in 100 mL 1x 
TBS-T 
 Primary antibody diluent: TBS-T with 5% BSA and 0.05% NaN3. Primary 
antibodies are prepared in a 50 mL Falcon Tube (5-10 mL per antibody). The 
antibodies are stored at 4°C and used multiple times 
 Secondary antibody diluent: Secondary antibodies are prepared freshly in 1% 
milk powder solution 
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2.13. Immunostaining  
 CGNs on coverslips were washed two times with PBS and then treated with 
ice-cold immuno-fix (3.7% formaldehyde in PBS) for 10 min. The cells were then 
washed three times with 0.5% BSA (in PBS) and incubated in 5% Normal Goat Serum 
(in 0.5% BSA solution) for 1 hour at room temperature. The cells were then washed 
two times with 0.5% BSA and incubated with mouse monoclonal antibody against III-
tubulin (Cell Signaling, 4466, 1:1000 in 0.5% BSA with 0.01% Triton X-100) for 1 h at 
room temperature. The cells were then washed two times with 0.5% BSA and then 
incubated with secondary antibody conjugated with Alexa 488 (goat anti-mouse IgG, 
Cell Signaling, A-11029, 1:100 in 0.5% BSA with 0.01%Triton X-100) and 1 µg/mL 
Hoechst 33258 (Sigma) for 30 min in the dark at room temperature. The cells were 
then washed three times with 0.5% BSA and mounted on glass slides with mounting 
medium (Shandon Immu-Mount, Thermo Scientific). The cells were photographed with 
the Axiovert 200 microscope setup. 
 
2.14. X-gal staining 
For cells: Transfer cells on coverslips into 6-well plate. Wash twice with 3 ml 
PBS. Fix cells with 2 ml pre-chilled Cell fix solution for 10 min at rt. (Important: work 
under chemical hood). Wash cells twice gently with 3 ml PBS. Incubate cells in 2 ml 
X-Gal staining solution for 3-12 h at 37 °C in the dark. Wash twice with 3 ml PBS.  
For tissues: Isolate tissue and then wash in a dish of PBS. Fix tissue with pre-chilled 
Cell fix solution for 30 min at rt and inverted gently every 5 min. (Important: work under 
chemical hood). Wash tissue twice with ~3 ml PBS. Incubate tissues in X-Gal staining 
solution for 3-12 h at 37 °C in the dark. Wash twice with 3 ml PBS.  
Materials 
 Cell fix: 2% Formaldehyde, 0.2% Glutaraldehyde in PBS, sore at 4 °C.  
 X-Gal stock solution: X-Gal (in DMSO, 40 mg/mL), store in 1 mL aliquots at  
-20 °C. 
 X-Gal staining solution: MgCl2 (2.0 mM), K3Fe(CN)6 (2.5 mM), K4Fe(CN)6 (2.5 
mM) in PBS, store at rt in the dark. X-Gal (1 mg/mL, always add fresh). 
 
 
2.15. -gal-NONOate activity in vivo as determined by VASP phosphorylation 
Susanne Feil (Interfaculty Institute of Biochemistry, University of Tübingen) assisted 
with data collection. To investigate β-gal-NONOate’s activity in vivo, wild type and SM-
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CreERT2 x R26-lacZ mice were used. SM-CreERT2 mice express the tamoxifen-
inducible CreERT2 recombinase under control of the smooth muscle-specific SM22 
promotor. To activate lacZ expression specifically in smooth muscle-specific SM22 
positive cells, 12-week-old and SM-CreERT2 mice were treated injected with 1 mg of 
tamoxifen once a day for five days via intraperitoneal injection. Mice were put under 
narcosis by Dr. Susanne Feil and then 50 L of saline (0.9% NaCl in H2O) or 50 L of 
β-gal-NONOate (3.5 mM in saline) was injected via the tail vein. 8.5 μL of β-gal-
NONOate (100 mM) was diluted in 241.5 μL saline for an end concentration of 3.5 
mM. Mice received a 50 μL injection resulting in a blood concentration of about 100 
μM assuming 2 mL of blood volume for the mouse. Then, 20 min after injection the 
mouse was sacrificed and the organs were isolated (heart, aorta, colon, bladder, 
skeletal muscle from the torso, and lungs). Tissues were halved with scissors. Half of 
all tissues were immediately transferred to lysis buffer solution (0.67% SDS (w/v), 21 
mM Tris/HCl (pH 8.3), 0.2 mM phenylmethylsulfonylfluoride, and one tablet of 
PhosSTOP™ phosphatase inhibitor cocktail (Roche) per 10 mL) and further prepped 
for protein extraction. Samples were stored at -20 °C before performing further 
analysis. Western blot was performed at a later date. The other halves were fixed and 
stained with x-gal overnight.  
 
2.16. Synthesis of -gal-NONOate  
 The synthesis was performed in the laboratories of Prof. Dr. Stafforst 
(Interfaculty Institute of Biochemistry, University of Tübingen) and Prof. Dr. Ziegler 
(Institute of Organic Chemistry, University of Tübingen) with help from Anne Stroppel 
(Interfaculty Institute of Biochemistry, University of Tübingen) and Gregor Lemanski 
(Institute of Organic Chemistry, University of Tübingen). Synthesis was conducted in 
a similar manner to the methodology reported previously [141]. The synthesis was a 
five-step reaction completed with an overall yield of 6%. The synthesis involved 
acetylation of the reactive alcohol groups, bromination of galactose at the anomeric 
carbon. The NONOate (diazeniumdiolate) was prepared under a high-pressure 
reaction with NO gas and pyrrolidine. Then the NONOate compound and the 
brominated, acetylated galactose were combined in a coupling reaction that produced 
only the anomer of the sugar due to inversion of stereochemistry via the Sn2 
reaction. The coupling reaction could be nicely followed because the galactose sugar 
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stains brown upon treatment with sulfuric acid and heat, while the NONOate is visible 
under UV light, as described below. Subsequent deprotection via hydrolysis and 
purification via column chromatography produced the final -gal-NONOate compound. 
 
Galactose protection via peracetylation 
1 g of peracetylated galactose were suspended in 2 ml of an ice-cold mixture of acetic 
acid and acetic anhydride (ratio 2:3). While stirring, 4 ml of 33% HBr-acetic acid were 
added dropwise within 30 min. Then the mixture is stirred for 30 minutes as it warms 
to rt. The mixture is stirred at rt for 2 h, then 20 ml of dichloromethane are added. The 
organic phase is washed with about 13 ml of ice-cold water and then three times with 
13 ml of ice-cold saturated sodium carbonate solution, then dried over sodium 
sulphate. The solvent was stripped off on a rotary evaporator and the brominated 
product is crystallized from diethyl ether. The resulting white solid (1,2,3,4,5-penta-O-
acetyl-β-D-galactopyranoside) was dried in vacuo and stored at -20 °C. Percent yield 
73%. 
 
 Bromination of the galactose anomeric carbon 
62.5 ml of 33% HBr in glacial acetic acid (1079 mmol, 1.1 eq) were carefully added 
dropwise to a solution of 25.0 g (64.4 mmol, 1 eq) of 1,2,3,4,5-penta-O-acetyl-β-D-
galactopyranoside in 250 ml DCM at 0 ° C. After complete addition, the reaction 
solution was stirred for 2 hours at rt. The reaction progress was tracked (TLC control: 
PE / EA 1: 1). Note: to visualize the sugar, spray the TLC plate with 5% sulfuric acid 
in methanol and then heat with a heat gun to produce a brown spot. Once the reaction 
was complete it was diluted with 200 ml of ice-water. The organic phase was washed 
with 100 ml of saturated NaHCO3 solution and once with 150 ml of water. Finally, the 
organic phase was dried over sodium sulfate and the solvent removed under vacuum. 
The product was a slightly brown colored oil. Percent yield 91%. 
 
Synthesis of the diazeniumdiolate  
Anne Stroppel (Interfaculty Institute of Biochemistry, University of Tübingen) and 
Gregor Lemanski (Institute of Organic Chemistry, University of Tübingen) performed 
the synthesis of the diazeniumdiolate.  
Note: This reaction uses the toxic gas NO under high pressures with a danger of 
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explosion. For more information see previous work [158]. 
1 ml of pyrrolidine was combined with 2.4 ml of sodium methoxide in methanol (5 M) 
in 20 ml of anhydrous methanol under a nitrogen atmosphere. Then the reaction 
mixture is placed under vacuum for a short time to remove all dissolved gases from 
the liquid solution. The reaction is then set to a pressure of 4 bar with NO and stirred 
vigorously for 3-4 h at rt. The reaction mixture is concentrated into a syrup and then 
taken up in diethyl ether in which the product precipitates as a white powder. It is 
filtered with diethyl ether and then dried under vacuum. The resulting diazeniumdiolate 
is stored under nitrogen and protected from light. Percent yield 28%.  
 
Glycosylation of the diazeniumdiolate 
1 g of diazeniumdiolate and 2 g of brominated, acetylated galactose are dissolved in 
30 ml of anhydrous acetonitrile and stirred for 24 h. The reaction mixture is protected 
from light in order to prevent radical side reactions of the liberated hydrogen bromide. 
The reaction progress was tracked (TLC control: PE / EA 1: 1). Note: the 
diazeniumdiolate product fluoresces under UV light while the sugar can be visualized 
with sulfuric acid as stated previously. The reaction mixture was concentrated on a 
rotary evaporator and taken up in 50 ml of ethyl acetate. The reaction was then shaken 
out three times with 50 ml of water and dried over sodium sulfate. The product was 
purified on a silica gel column with a 1: 1 mixture of ethyl acetate and petroleum ether. 
Percent yield 38%. 
 
Deacetylation of the -D-Galactopyranosyl 1-(pyrrolidine-1-yl)-diazenium-1,2-
diolate (acetylated -gal-NONOate) 
1 g of -D-Galactopyranosyl 1-(pyrrolidine-1-yl)-diazenium-1,2-diolate is dissolved in 
50 ml of anhydrous methanol. Sodium methoxide is added until the pH is at least 8-9; 
a higher pH does not appear to disrupt the reaction. The mixture was stirred for 2 h at 
rt and then purified on a silica gel column using a 1:10 mixture of methanol and 
chloroform as eluent. The product was then set under vacuum and the final product 
collected as a white solid. The resulting -gal-NONOate was protected from light and 
moisture and stored at 4 °C. Percent yield 86%. Nuclear magnetic resonance (NMR) 
spectra were produced by BrukerAvance III HDX 400 spectrometer at 400.16 MHz for 
proton NMR spectra. The 1H NMR was collected at the NMR facility (Institute of 
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Organic Chemistry, University of Tübingen) with help from the Stafforst Laboratory 
(Interfaculty Institute of Biochemistry, University of Tübingen). The complete five-step 
synthesis was completed with an overall yield of 6% resulting in 110 mg of -gal-
NONOate. 
 
 
2.17. Data analysis and statistics  
Imaging data were analysed as previously described [118]. For image acquisition and 
online analysis, VisiView (Visitron) was used, and for offline analysis Fiji software 
(NIH) [154]. For further analysis, Microsoft Excel (Microsoft Corp.) and Origin 
(OriginLab Corp.) were used. F480 signals (CFP emission at 480 nm, cyan traces in 
respective graphs) and F535 signals (YFP emission at 535 nm, orange traces in 
respective graphs) were background-corrected and used to calculate the F480/F535 ratio 
R (green traces in respective graphs). F340 signals (intensity of emission at 535 nm 
after excitation at 340 nm) and F387 signals (intensity of emission at 535 nm after 
excitation at 387 nm) were background-corrected and used to calculate the F340/F387 
ratio R (black traces in respective graphs). ΔF480/F480, ΔF535/F535, ΔF340/F340, ΔF387/F387 
and corresponding ΔR/R traces were obtained by normalization to the baseline 
recorded for ~3 min at the beginning of each experiment. For ΔR/R peak area and 
peak height calculation, Peak Area/Height Analyzer of Origin was used. Peak borders 
were defined manually. Statistical analysis was performed using Origin software. 
Statistical differences between more than two groups were analyzed by one-way 
ANOVA followed by Bonferroni’s test. p values < 0.05 were considered to be 
significant.
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3 Results 
3.1. NO-cGMP signaling in CGNs 
As discussed in the introduction, the cGMP signaling pathway has proven itself 
highly drugable (Table 1). However, information about this pathway in the nervous 
system is limited and in need of further investigation. To this end, we have investigated 
the cGMP signaling components in CGNs.  
3.1.1. cGMP imaging in CGNs reveals a NO-induced cGMP response  
Primary CGN cultures were prepared from 7-day-old R26-cGi500-L1 mice [118], 
which express the cGi500 sensor ubiquitously. As shown in Figure 10, CGNs 
expressed the cGMP sensor protein (Figure 10A, green fluorescence). It is important 
to note that the green fluorescence shown in Figure 10A shows the YFP emission of 
the sensor and not the cGMP concentration, which is reflected by the CFP/YFP 
emission ratio. To determine which substances can induce a reliable elevation of 
cGMP in CGNs, the cells were exposed to ANP (100 nM), CNP (100 nM), or the 
NO-releasing compound diethylamine NONOate (DEA/NO) (100 nM) during real-time 
imaging under continuous flow (Figures 10A and B). Application of DEA/NO induced 
a robust cGMP elevation as indicated by a simultaneous increase in CFP emission 
(cyan trace) and decrease in YFP emission (orange trace) resulting in an increased 
CFP/YFP ratio (black trace) (Figure 10B). Application of ANP or CNP did not result in 
a cGMP increase. To determine the sensitivity of the cGMP response of CGNs to 
DEA/NO, a concentration-response curve experiment was performed and revealed an 
EC50 of 32 nM (Figure 10C). CGN primary cultures were immunostained with III-
tubulin (neuronal marker, green) and nuclei with Hoechst dye (blue) to confirm they 
are neurons (Figure 10D). We then wanted to compare the results in tissue slices.  
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Figure 10. Visualization of cGMP in CGNs reveals a NO-induced cGMP response. 
(A) CGNs isolated from 7-day-old R26-cGi500-L1 mice express the cGi500 sensor (green). The 
green color represents the YFP fluorescence of cGi500. Scale bar 10 m. (B) cGMP 
measurement in CGNs upon stimulation with DEA/NO (100 nM), ANP (100 nM), and CNP 
(100 nM). Black, cyan, and orange traces represent CFP/YFP ratio, CFP emission, and YFP 
emission, respectively. Scale bars represent the change in fluorescence of the single 
fluorophores CFP or YFP (ΔF/F) or their ratio (CFP/YFP; ΔR/R reflecting [cGMP]i). The signals 
are from a single cell representative of the data set (n = 57 cells measured on six coverslips 
obtained from three independent cultures). (C) Increasing concentrations of DEA/NO were 
applied to CGNs to establish a concentration-response curve. The EC50 of CGNs for DEA/NO 
is 32 nM. Data are presented as mean ± SEM (n = 12 cells per data point; cells from one culture 
were measured on one coverslip). (D) Representative picture of a CGN primary culture 
stained for III-tubulin (neuronal marker, green) and nuclei with Hoechst dye (blue); an 
overlay of both channels is also shown (Merge). Scale bar 10 µm. 
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3.1.2. cGMP imaging in acute cerebellar slices reveals a NO-induced cGMP 
response  
cGMP was also visualized in freshly prepared cerebellar slices isolated from R26-
cGi500-L1 mice, which express the cGi500 sensor ubiquitously. The cerebellar tissue 
slices fluoresce green, which is the expressed cGMP sensor protein (Figure 11A, 
green fluorescence). It is important to note that the green fluorescence shown in Figure 
11A is the YFP emission of the sensor and not the cGMP concentration, which is 
reflected by the CFP/YFP emission ratio. To determine which substances can induce 
a reliable elevation of cGMP in cerebellar slices, the tissue was exposed to ANP (250 
nM), CNP (250 nM) and DEA/NO (5 µM) during real-time imaging under continuous 
flow. As in the CGN cultures, cGMP was elevated in acute cerebellar slices upon 
DEA/NO application, but not ANP nor CNP (Figure 11B, black trace). We then wanted 
to investigate the relationship between NO-induced cGMP and Ca2+ responses in 
CGNs. 
 
 
 
Figure 11. Visualization of cGMP in acute cerebellar slices reveals a NO-induced cGMP 
response. 
(A) Acute cerebellar slice isolated from a 7-week-old R26-cGi500-L1 mouse. The green color 
represents the YFP fluorescence of cGi500. Scale bar 20 µm. (B) cGMP measurement in the 
granule cell layer of a cerebellar slice upon stimulation with ANP (250 nM), CNP (250 nM), 
and DEA/NO (5 µM). Black, cyan, and orange traces represent CFP/YFP ratio, CFP emission, 
and YFP emission, respectively. Scale bars represent the change in fluorescence of the single 
fluorophores CFP or YFP (ΔF/F) or their ratio (CFP/YFP; ΔR/R reflecting [cGMP]i). The signals 
are from a single region of interest representative of the data set (n = 3 acute cerebellar slices 
analyzed in three independent experiments). 
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3.1.3. Simultaneous imaging of Ca2+ and cGMP reveals NO potentiation of 
glutamate-induced Ca2+ transients in CGNs 
To investigate the potential crosstalk between NO-cGMP signaling and Ca2+ 
signaling, cGMP and Ca2+ were simultaneously measured under flow in real-time in 
CGNs isolated from sensor mice (R26-cGi500-L1). The CGNs were loaded with the 
fluorescent Ca2+ indicator Fura-2 and then stimulated with glutamate to induce a Ca2+ 
response and DEA/NO to induce a cGMP response (Figure 12). Figure 12A depicts 
the control stimulation without the addition of DEA/NO. CGNs were exposed to 
glutamate (100 M, 9.6 s) to evoke Ca2+ transients (black trace) twice per 
measurement. There were no observed changes in cGMP concentration (green trace) 
during glutamate-induced Ca2+ transients (black trace). Figure 12B shows a 
representative trace during stimulation with both glutamate and DEA/NO (100 nM). 
Glutamate addition during NO-induced elevated cGMP levels resulted in augmented 
glutamate-induced Ca2+ transients compared to control Ca2+ transients in the absence 
of DEA/NO (Figures 12A-C). The evaluation was performed by taking the ratio of the 
peak height of the second Ca2+ transient (in the presence of Tyrode buffer or DEA/NO) 
and the peak height of the first Ca2+ transient (in the absence of DEA/NO) (2nd peak 
height : 1st peak height). Analysis revealed a second peak to first peak height ratio of 
1.2 vs. 0.7 (Figure 12C; p < 0.001). These data depicted a NO-induced 
augmentation of glutamate-induced Ca2+ transients in primary mouse CGNs. 
To determine if the observed augmented Ca2+ transients is cGMP dependent and 
not an NO-induced cGMP-independent effect, CGN cultures were prepared from 
cGMP sensor mice lacking the β1 subunit of NO-GC (NO-GC KO) [144] that therefore 
expressed no functional NO-GC. These CGNs showed normal glutamate-induced 
Ca2+ transients (Figure 12D, black trace; Figure 3F, Tyrode). As expected, NO-GC 
KO CGNs showed no increase in the cGMP concentration upon addition of DEA/NO 
(100 nM) (Figure 12E, green trace), confirming the absence of functional NO-GC in 
these cells. In contrast to wild type CGNs (Figures 12A-C), NO-GC KO cells showed 
similar glutamate-induced Ca2+ transients in the absence and presence of DEA/NO, 
supporting the notion that the NO-induced augmentation of Ca2+ transients is indeed 
cGMP-dependent (Figures 12D-F). After confirming our hypothesis with the NO-GC 
KO CGNs, we wanted to use pharmacological tools to further test the importance of 
cGMP in the observed crosstalk.  
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Figure 12. Simultaneous measurement of cGMP and Ca2+ reveals cGMP-Ca2+ crosstalk 
in CGNs. 
Traces depict cGMP (green) visualized with the cGi500 sensor, and [Ca2+]i (black) visualized 
with Fura-2. CGNs were exposed to glutamate (100 μM) (for 9.6 s, represented by vertical 
arrows) to elevate [Ca2+]i, and to DEA/NO (100 nM) (represented by horizontal bars) to 
increase the cGMP concentration. Tyrode buffer was used as a control in the absence of 
DEA/NO. Traces depict representative measurements of individual cells. Scale bars represent 
the change in fluorophore ratio (ΔR/R reflecting [cGMP]i or [Ca2+]i). (A-C) Imaging of cGi500-
expressing CGNs with NO-GC wild type alleles (wild type). (A) Brief repetitive stimulation with 
glutamate under control conditions. (B) CGNs were exposed to glutamate alone and then to 
DEA/NO followed by a second stimulation with glutamate in the presence of DEA/NO. (C) 
Quantification of the results obtained under conditions shown in (A) and (B). Depicted is the 
ratio of the [Ca2+]i peak heights (2nd over 1st peak) of individual cells. Data are presented as 
mean ± SEM; p < 0.001*** (n = 17 cells for Tyrode, n = 25 cells for DEA/NO, measured on six 
coverslips obtained from three independent cultures). (D-F) Imaging of cGi500-expressing 
CGNs with a genetic deletion of NO-GC (NO-GC KO). (D) Brief repetitive stimulation with 
glutamate under control conditions. (E) CGNs were exposed to glutamate alone and then to 
DEA/NO followed by a second stimulation with glutamate in the presence of DEA/NO. (F) 
Quantification of the results obtained under conditions shown in (D) and (E). Depicted is the 
ratio of the [Ca2+]i peak heights (2nd over 1st peak) of individual cells. Data are presented as 
mean ± SEM; n.s., not significant (n = 90 cells for Tyrode, n = 60 cells for DEA/NO, measured 
on twelve coverslips obtained from two independent cultures). The NO-GC KO mouse lines 
were originally developed by the Friebe laboratory (Institute of Physiology, Julius-Maximilians-
University). 
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3.1.4. cGMP analogues support a cGMP-dependent increase of glutamate-
induced Ca2+ transients 
To further investigate the importance of cGMP in augmented glutamate-induced 
Ca2+ responses, the membrane-permeable cGMP analogue 8-Br-cGMP (100 M) or 
8-pCPT-cGMP (100 M) was applied in place of DEA/NO during glutamate-induced 
Ca2+ transients. In the presence of 8-Br-cGMP or 8-pCPT-cGMP, glutamate-induced 
Ca2+ transients were significantly augmented compared to controls without cGMP 
analogues (Figure 13A, p <0.05; Figure 13B, p <0.01). The results with cGMP 
analogues further support a cGMP-Ca2+ crosstalk in CGNs, which could be mediated 
via cGKs, CNG channels, or other cGMP effector proteins. Our next experiment aimed 
to identify the cGMP-effector proteins that were possibly involved in this crosstalk.  
 
 
 
Figure 13. The addition of cGMP analogues confirms cGMP-Ca2+ crosstalk in CGNs. 
(A) Quantification of glutamate (100 µM, 9.6 s)-induced elevation of [Ca2+]i in the absence of 
cGMP analogue (Tyrode) or after pre-incubation of cells with 8-Br-cGMP (100 µM, 5.5 min). 
Data are depicted as the ratio of the [Ca2+]i peak heights of individual cells (2nd over 1st peak, 
where the 2nd peak was induced by glutamate in the presence of Tyrode or 8-Br-cGMP) and 
presented as mean ± SEM; p < 0.05* (n = 15 cells for Tyrode, n = 34 cells for 8-Br-cGMP, 
measured on seven coverslips obtained from three independent cultures). (B) Quantification 
of glutamate (100 µM, 10 s)-induced elevation of [Ca2+]i in the absence of cGMP analogue 
(Tyrode) or after pre-incubation of cells with 100 µM 8-pCPT-cGMP for 5.5 min. Data are 
depicted as the ratio of the [Ca2+]i peak heights of individual cells (2nd over 1st peak, where the 
2nd peak was induced by glutamate in the presence of Tyrode or 8-pCPT-cGMP) and 
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presented as mean ± SEM; p < 0.01** (n = 29 cells for Tyrode, n = 22 cells for 8-pCPT-cGMP, 
measured on six coverslips obtained from two independent cultures). 
 
3.1.5. CGN primary cultures do not express cGKI nor cGKII as determined by 
Western blot analysis 
To determine if cGKs could be downstream targets of cGMP, protein lysates from 
CGN primary cultures were analyzed via Western blot with cGKI and cGKII antibodies 
(Figures 14 and 15). All antibodies were validated with respective knockout tissues 
to confirm their specificity. While the cGKI protein was readily detected in lysates from 
colon and cerebellum isolated from wild type mice, it was not detected in our primary 
CGNs (Figure 14). Using a highly specific antibody made in the laboratory of Prof. Dr. 
Jens Schlossmann (Department of Pharmacology and Toxicology, University of 
Regensburg) , the cGKII protein was detected in lysates from jejunum of wild type 
mice as well as in cerebellum isolated from wild type or cGKI knockout mice, but it was 
not detected in our CGN lysates (Figure 15A). Another cGKII antibody from 
Proteintech proved to be of limited use to detect cGKII, but rather stained several 
unknown protein bands including one in CGNs with a molecular weight of about 72 
kDa (Figure 15B). These data indicate that neither cGKI nor cGKII are expressed in 
our primary cultured CGNs and thus do not play a role in cGMP/Ca2+ crosstalk. These 
data also highlight the importance of antibody validation with positive and knock-out 
controls. We next wanted use real-time imaging to investigate the specific PDEs 
involved in cGMP degradation in CGNs. 
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Figure 14. Western blot analysis reveals no cGKI expression in primary CGN cultures. 
Lysates prepared from CGN cultures grown for 5 days in vitro (10 μg), colon (10 μg) and 
cerebellum of a wild type mouse (wt) (10 μg) as well as cerebellum of a cGKI knockout mouse 
(cGKI KO) (10 μg) were stained with a highly specific cGKI antibody. GAPDH was used as a 
loading control. Representative data from three independent CGN primary cultures are 
shown. Expected molecular weights of respective proteins are indicated on the right. CGN 
cultures were established from 7-day-old wild type mice (wt P7) and extracts of the 
cerebellum and internal organs were prepared from 8- to 25-week-old mice. 
 
 
 
Figure 15. Western blot analysis reveals no cGKII expression in primary CGN cultures. 
(A) Lysates prepared from three CGN cultures grown for 5 days in vitro (30 μg). jejunum (20 
µg) and cerebellum of a wild type mouse (wt) (70 µg) as well as cerebellum of a cGKI 
knockout mouse (cGKI KO) (70 µg) and of a cGKII knockout mouse (cGKII KO) (70 µg) were 
stained with a highly specific cGKII antibody. β-actin was used as a loading control. Expected 
molecular weights of respective proteins are indicated on the right. CGN cultures were 
established from 7-day-old wild type mice (wt P7) and extracts of the cerebellum and internal 
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organs were prepared from 8- to 25-week-old mice. (B) Lysates prepared from three CGN 
cultures grown for 5 days in vitro (30 μg). jejunum (20 µg) and cerebellum of a wild type 
mouse (wt) (70 µg) as well as cerebellum of a cGKI knockout mouse (cGKI KO) (70 µg) and 
of a cGKII knockout mouse (cGKII KO) (70 µg) were stained with a cGKII antibody from 
Proteintech. The black arrow represents the band that is potentially cGKII. β-actin was used 
as a loading control. Representative data from two independent Western blots are shown. 
Expected molecular weights of respective proteins are indicated on the right. CGN cultures 
were established from 7-day-old wild type mice (wt P7) and extracts of the cerebellum and 
internal organs were prepared from 8- to 25-week-old mice. The Western blots were 
performed with help from Prof. Dr. Jens Schlossmann and Andrea Schramm (Department of 
Pharmacology and Toxicology, University of Regensburg).  
 
 
3.1.6. Real-time cGMP imaging in CGNs reveals cGMP degradation via 
Zaprinast-sensitive PDEs 
To evaluate which PDE(s) degrade cGMP in murine CGNs, the cells were exposed 
to various PDE inhibitors. CGNs from cGMP sensor mice were first superfused with 
DEA/NO (50 nM) alone (Figure 16A, first peak), and then with the general PDE 
inhibitor IBMX (100 µM) followed by DEA/NO (50 nM) in the presence of IBMX (Figure 
16A, second peak) and a final application of DEA/NO (50 nM) alone (Figure 16A, third 
peak). IBMX alone had no influence on the basal cGMP level in cultured CGNs, 
however, it strongly potentiated the cGMP increase elicited by DEA/NO compared to 
DEA/NO alone (Figure 16A). To identify the PDEs that play a role in cGMP 
degradation in CGNs, specific PDE inhibitors [69] were applied in the same manner 
as shown for IBMX in Figure 16A. These PDE inhibitors were Vinpocetine (5 µM) for 
PDE1, Bay 60-7550 (10 nM) for PDE2, EHNA (10 µM) for PDE2, Milrinone (10 µM) for 
PDE3, Sildenafil (20 µM) for PDE5, and Zaprinast (20 µM) for PDE5, 6, 9, 10, and 11. 
These measurements (Figure 16B) revealed a weak but significant effect of Sildenafil 
(p < 0.05) and a strong effect of Zaprinast (p < 0.05). The other tested PDE inhibitors 
did not show statistically significant effects on NO-induced cGMP elevation. These 
data implicated PDE5, 6, 9, 10, and 11 as possible cGMP-degrading PDEs in murine 
CGNs. 
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Figure 16. Real-time cGMP imaging in CGNs reveals degradation of cGMP by Zaprinast-
sensitive PDEs. 
(A) cGi500-expressing CGNs isolated from R26-cGi500-L1 mice were stimulated three times 
with DEA/NO (50 nM), first with DEA/NO alone, then in the presence of IBMX (100 µM), 
and finally again with DEA/NO alone. The bar graph shows the statistical evaluation of 
DEA/NO-induced cGMP peak areas before (1st peak), during (2nd peak) and after (3rd peak) 
incubation with IBMX. Peak areas were normalized to the 1st peak of each experiment. Data 
are presented as mean ± SEM; p < 0.05* 1st versus 2nd peak (n = 6 cells measured on three 
coverslips obtained from three CGN cultures). (B) As described for (A), CGNs were 
superfused with DEA/NO (50 nM) in the absence and presence of indicated PDE inhibitors. 
The following PDE inhibitors were tested: 5 µM Vinpocetine (Vin); 10 nM Bay 60-7550 (Bay); 
10 µM EHNA; 10 µM Milrinone (Mil); 20 µM Sildenafil (Sil); 20 µM Zaprinast (Zap). Data are 
presented as mean ± SEM; p < 0.05* 1st versus 2nd peak (n= 6-12 cells per condition; cells were 
measured on two coverslips obtained from two CGN cultures). Data were collected and 
evaluated by Stefanie Peters (Interfaculty Institute of Biochemistry, University of Tübingen).  
 
3.2. Cell type specific NO release with -gal-NONOate 
As mentioned previously, traditional NO releasing compounds act ubiquitously on 
all cell types [140]. It was our aim to enable cell type specific NO release to facilitate 
more accurate investigation of NO signaling. To this end, we planned to use -gal-
NONOate, which only releases NO in the presence of -galactosidase, in combination 
with lacZ under the control of cell-specific Cre/loxP mouse lines. We investigated the 
viability of this methodology to enable cell type specific NO generation in cell cultures, 
acute tissue slices, and in vivo.  
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3.2.1. Synthesis of -gal-NONOate  
Due to limited availability and high costs from commercial sources, we synthesized 
-gal-NONOate ourselves in collaboration with the laboratories of Prof. Dr. Stafforst 
(Interfaculty Institute of Biochemistry, University of Tübingen) and Prof. Dr. Ziegler 
(Institute of Organic Chemistry, University of Tübingen). The overall yield for the five-
step synthesis was ~6% resulting in 110 mg of -gal-NONOate. Proton nuclear 
magnetic resonance (1H NMR) analysis was performed and chemical shifts are in ppm 
(Figure 17). The 1H NMR shows us the chemical shifts of the unique protons in the 
synthesized compound and helps to confirm the molecule’s structure [159]. The 
integration of the 1H NMR signals is proportional to the ratio of the protons in the 
molecule [159].  
The synthesis of -gal-NONOate was performed in five steps (Figure 18). The first 
reaction was an acetylation protection reaction of the alcohol groups on the galactose 
ring. This was then followed by bromination to facilitate the subsequent coupling 
reaction. The NONOate salt (diazeniumdiolate) was synthesized under high pressure 
with NO gas (~4 bar) and pyrrolidine. The diazeniumdiolate was then combined with 
the brominated, galactose to produce acetylated -gal-NONOate. Deprotection and 
subsequent purification via column chromatography were performed to produce the 
final product -gal-NONOate. For more information refer to section 2.16. After 
successful synthesis of -gal-NONOate, we wanted to test its ability to induce NO-
cGMP signalling in living cells and tissues.  
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Figure 17. 1H NMR spectrum of the end product. 
Proton NMR spectra were produced by BrukerAvance III HDX 400 spectrometer at 400.16 
MHz. 1H NMR (400 MHz, CD3OD): δ 7.88 (s, 1H), 4,83-4.77 (m, 4H), 4.50 (dd, 2H), 3.77–3.47 
(m, 4H), 3.22 (s, 2H), 2.06–1.93 (m, 4H). The 1H NMR was collected with help from the NMR 
facility (Institute of Organic Chemistry, University of Tübingen) and the Stafforst Laboratory 
(Interfaculty Institute of Biochemistry, University of Tübingen). 
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Figure 18. Synthesis of -gal-NONOate. 
The synthesis was completed in five reaction steps. -galactose was protected via acetylation. Then HBr was used to prime the sugar for Sn2 addition of the 
NONOate salt. In a separate reaction, pyrrolidine was mixed with sodium methoxide and NO gas under high pressure (4 bar) to produce the NONOate salt. 
The NONOate was then combined with the brominated galactose in a coupling reaction. The acetylated-gal-NONOate was deprotected to yield the final 
product. The -gal-NONOate compound was synthesized with help from the lab of Prof. Dr. Stafforst (Interfaculty Institute of Biochemistry, University of 
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Tübingen), Anne Stroppel (Interfaculty Institute of Biochemistry, University of Tübingen), the lab of Prof. Dr. Ziegler (Institute of Organic Chemistry, University 
of Tübingen) and Gregor Lemanski (Institute of Organic Chemistry, University of Tübingen).
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3.2.2. Real-time cGMP imaging in VSMCs with -gal-NONOate  
We then wanted to determine if our synthesized -gal-NONOate could elevate 
cGMP in biological models. For this, VSMCs were isolated from 8-12-week-old R26-
cGi500-L1 mice (Figures 19A and 20A), which express the cGi500 sensor 
ubiquitously. The VSMCs fluoresce green because of the expressed cGMP sensor 
protein (Figures 19A and 20A, green fluorescence). It is important to note that the 
green fluorescence is the YFP emission of the sensor and not the cGMP 
concentration, which is reflected by the CFP/YFP emission ratio. To achieve 
expression of -galactosidase, VSMCs were transfected with the -galactosidase 
encoding plasmid pFRTgal and then stained with x-gal, where -galactosidase 
positive VSMCs appear dark blue (Figure 19B). Other VSMCs were not transfected 
and used as a negative control (Figure 20B). To determine if -gal-NONOate can 
reliably induce an elevation of cGMP in -galactosidase expressing VSMC cultures, 
the cells were exposed to -gal-NONOate (50 M) and the positive control DEA/NO 
(100 M) during continuous superfusion (Figures 19C-E). The addition of -gal-
NONOate resulted in an elevation in cGMP levels in 62% of VSMCs and the addition 
of the positive control DEA/NO resulted in a response in all VSMCs (Figures 19C-E). 
Some VSMCs displayed a strong elevation in cGMP upon the addition of -gal-
NONOate (Figure 19C), others showed weak cGMP elevation upon the addition of -
gal-NONOate (Figure 19D), while another subset of VSMCs revealed no cGMP 
elevation upon the addition of -gal-NONOate (Figure 19E). Control cells (no 
-galactosidase expression) were exposed to -gal-NONOate (50 M, 100 M) and 
the positive control DEA/NO (100 M) during continuous superfusion (Figures 20C 
and D). The addition of -gal-NONOate did not elevate cGMP levels, whereas the 
positive control DEA/NO did (Figures 20C and D). Some VSMCs displayed a strong 
elevation in cGMP upon the addition of DEA/NO (Figure 20C), while others showed 
weak cGMP elevation upon the addition of DEA/NO (Figure 20D). These data 
demonstrate that -gal-NONOate induces cGMP synthesis only in -galactosidase 
expressing cultures and does not spontaneously release NO. Therefore, -gal-
NONOate appeared to be a suitable tool for cell-type targeted NO generation and 
intracellular cGMP elevation. To further investigate this, we next tested -gal-
NONOate in acute cerebellar brain slices.  
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Figure 19. -gal-NONOate elevates cGMP in VSMC cultures expressing -galactosidase. 
(A) VSMCs isolated from 8-12-week-old R26-cGi500-L1 mice expressing the cGi500 sensor 
(green) were transfected with the -galactosidase encoding plasmid pFRT-gal. The green 
color represents the YFP fluorescence of cGi500. (B) A bright field view of the same VSMCs 
to show the -galactosidase positive cells (7%) that are indicated with black arrows. (C-E) 
VSMCs expressing -galactosidase were exposed twice to -gal-NONOate (NONOate) (50 
M) during continuous superfusion. DEA/NO (100 nM) was applied as a positive control. 
Black, cyan, and orange traces represent CFP/YFP ratio, CFP emission, and YFP emission, 
respectively. Scale bars represent the change in fluorescence of the single fluorophores CFP 
or YFP (ΔF/F) or their ratio (CFP/YFP; ΔR/R reflecting [cGMP]i). (C) VSMC 1 is a 
representative cell that showed a strong cGMP elevation upon -gal-NONOate addition. 
cGMP was elevated upon exposure to DEA/NO (VSMC 1, n = 15/74 cells, measured on three 
coverslips obtained from one culture). (D) VSMC 2 is a representative cell that showed weak 
cGMP elevation upon -gal-NONOate addition. cGMP was elevated upon exposure to 
DEA/NO (VSMC 2, n = 31/74 cells, measured on three coverslips obtained from one culture). 
(E) VSMC 3 is a representative cell that did not show cGMP elevation upon -gal-NONOate 
addition. cGMP was elevated upon exposure to DEA/NO (VSMC 3, n = 28/74 cells, measured 
on three coverslips obtained from one culture).  
 
Results 
 
65  
 
Figure 20. -gal-NONOate does not elevate cGMP in VSMC cultures lacking  
-galactosidase. 
(A) VSMCs isolated from 8-12-week-old R26-cGi500-L1 mice expressing the cGi500 sensor 
(green). The green color represents the YFP fluorescence of cGi500. (B) A bright field view of 
the same VSMCs to show the absence of lacZ positive cells. (C, D) VSMCs were exposed to -
gal-NONOate (NONOate) (50 M, 100 M) during continuous superfusion. DEA/NO (100 
nM) was applied at the end as a positive control. Black, cyan, and orange traces represent 
CFP/YFP ratio, CFP emission, and YFP emission, respectively. Scale bars represent the change 
in fluorescence of the single fluorophores CFP or YFP (ΔF/F) or their ratio (CFP/YFP; ΔR/R 
reflecting [cGMP]i). (C) VSMC 1 is a representative cell that showed no cGMP elevation upon 
the addition NONOate and a strong cGMP elevation in response to DEA/NO (n = 61/93 cells, 
measured on two coverslips obtained from one culture). (D) VSMC 2 is a representative cell 
that showed no cGMP elevation upon the addition NONOate and a weak cGMP elevation in 
response to DEA/NO (n = 32/93 cells, measured on two coverslips obtained from one culture).  
 
3.2.3. Real-time cGMP imaging in Purkinje cells in acute cerebellar slices with 
-gal-NONOate  
After demonstrating the efficacy of -gal-NONOate to elevate cGMP in cell culture, 
we wanted to test it in tissue slices. To this end, we measured cGMP in Purkinje cells 
in acute cerebellar slices prepared from mice with the lacZ gene and cGi500 sensor 
expression under the control of a Purkinje cell specific promotor (L7-Cre (tg/+) x R26-
lacZ (L2/lacZ) x R26-cGi500-L2 (L2/lacZ)), where ‘+‘ denotes the wild-type allele, ‘tg’ 
denotes the transgene. (Figure 21A). Control mice expressed only the cGi500 sensor 
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under the control of a Purkinje cell specific promotor without lacZ (L7-Cre (tg/+) x R26-
lacZ (+/L2) x R26-cGi500-L2 (+/L2)) (Figure 21D). The presence and absence of 
-galactosidase expression was confirmed by x-gal staining (Figures 21B and E). 
-gal-NONOate was applied to acute cerebellar slices via superfusion to determine if 
the compound is able to release NO and induce an elevation of cGMP in Purkinje cells. 
Indeed, mice expressing the cGi500 sensor and lacZ in Purkinje cells showed an 
elevation of cGMP upon the addition of -gal-NONOate (25 M) or the positive control, 
DEA/NO (5 M) (Figure 21C). No increase in cGMP was observed in mice expressing 
the cGi500 sensor without lacZ in Purkinje cells upon the addition of -gal-NONOate 
(5 M), but the positive control DEA/NO (5 M) did increase cGMP as expected 
(Figure 21F). These data supported the ability of -gal-NONOate to release NO in a 
lacZ-controlled manner in specific cell types of acute tissue slices. However, the 
question remained if -gal-NONOate was able to influence downstream cGMP 
effectors. To investigate this, we injected mice with -gal-NONOate and then 
investigated phosphorylation of the downstream molecule VASP via Western blot 
analysis.  
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Figure 21. -gal-NONOate elevates cGMP in Purkinje cells in the presence of  
-galactosidase. 
(A) Acute cerebellar slices isolated from 2-8-month-old (L7-Cre (tg/+) x lacZ (lacZ/L2) x R26-
cGi500-L2 (lacZ/L2)) mice expressing lacZ and the cGi500 sensor only in Purkinje cells (green). 
The green color represents the YFP fluorescence of cGi500. The white arrow shows the cell 
that is depicted in Figure 21C. (B) A bright field view of x-gal stained cerebellar slice to show 
the -galactosidase positive cells. The Purkinje layer is clearly positive. (C) Acute cerebellar 
slices expressing the cGi500 sensor and -galactosidase only in Purkinje cells were exposed to 
DEA/NO (5 M) as a positive control and to -gal-NONOate (NONOate) (25 M) during 
continuous superfusion. Black, cyan, and orange traces represent CFP/YFP ratio, CFP 
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emission, and YFP emission, respectively. Scale bars represent the change in fluorescence of 
the single fluorophores CFP or YFP (ΔF/F) or their ratio (CFP/YFP; ΔR/R reflecting [cGMP]i). 
The signals are from a single representative cell indicated in panel A (n = 9 cells, measured in 
three acute cerebellar slices obtained from three independent mice). (D) Acute cerebellar 
slices isolated from 2-8-month-old (L7-Cre (tg/+) x lacZ (+/L2) x R26-cGi500-L2 (+/L2)) mice 
expressing the cGi500 sensor only in Purkinje cells (green) without lacZ expression. The green 
color represents the YFP fluorescence of cGi500. The white arrow shows the cell that is 
depicted in Figure 21F. (E) A bright field view of x-gal stained cerebellar slice to show the 
absence of lacZ positive cells. (F) Acute cerebellar slices expressing the cGi500 sensor only in 
Purkinje cells were exposed to DEA/NO (5 M) as a positive control and to -gal-NONOate 
(NONOate) (5 M) during continuous superfusion. Black, cyan, and orange traces represent 
CFP/YFP ratio, CFP emission, and YFP emission, respectively. Scale bars represent the change 
in fluorescence of the single fluorophores CFP or YFP (ΔF/F) or their ratio (CFP/YFP; ΔR/R 
reflecting [cGMP]i). The signals are from a single representative cell indicated in panel D (n = 
four cells, measured in one acute cerebellar slice obtained from one mouse). 
 
 
3.2.4. -gal-NONOate-induced VASP phosphorylation in vivo 
After demonstrating the efficacy of -gal-NONOate in cell culture and tissue 
slices, we wanted to test it in the in vivo situation. Mice expressing -galactosidase 
specifically in smooth muscle cells (SM-CreERT2 (tg/+) x R26-lacZ (+/lacZ) x ApoE (+/-
)) and control mice without -galactosidase expression (SM-CreERT2 (tg/+) x R26-lacZ 
(+/+) x ApoE (+/-)) were injected with -gal-NONOate to determine if the compound 
induces VASP-phosphorylation via NO release and cGMP elevation as investigated 
via Western blot. VASP phosphorylation can can be visualized via Western blot by 
using an antibody that detects both unphosphorylated and phosphorylated VASP, 
which migrate at 46 kDa and 50 kDa, respectively [156]. VASP-phosphorylation is 
used as a measurement of cAK or cGK activity and thus indirectly cGMP or cAMP 
levels. 
Mouse 1, 3, and 4 were anesthetized and injected with -gal-NONOate (50 L, 
3.5 mM) via tail vein injection, which should result in blood concentration of about 100 
M assuming 2 mL of blood volume for the mouse. Mouse 2 was anesthetized and 
injected with saline solution (50 L) via tail vein injection. After 20 min, the organs 
(bladder, colon, aorta, lung, skeletal muscle, heart) were isolated and placed into  
x-gal staining solution to determine -galactosidase expression (Figure 22) or lysis 
buffer for protein isolation and subsequent detection of VASP-phosphorylation by 
Western blotting (Figure 23). Mice expressing -galactosidase (Mouse 1 and 3; 
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Figures 22 and 23) revealed increased VASP-phosphorylation in tissues with smooth 
muscle cells (bladder, colon, aorta, and lung) compared to control tissues lacking 
smooth muscle cells (skeletal muscle and heart) and control mice completely lacking 
-galactosidase (Mouse 2 and 4; Figures 22 and 23). Mouse 1 and 3 (SM-CreERT2 
(tg/+) x R26-lacZ (+/lacZ) x ApoE (+/-)) show x-gal positive staining in the bladder and 
colon and negative x-gal staining in the skeletal muscle and heart (Figures 22A and 
C). Mouse 1 showed some weak positive x-gal staining in the lung and no visible x-
gal staining in the aorta (Figures 22A). Mouse 3 showed no visible x-gal staining in 
the aorta and lung (Figures 22C). Mouse 2 (C57BL/6) and mouse 4 (SM-CreERT2 
(tg/+) x R26-lacZ (+/+) x ApoE (+/-)) were x-gal negative in all tissues, as expected 
(Figures 22B and D). Phosphorylated VASP is visible in the Western blot as the upper 
band at 50 kDa and unphosphorylated VASP is visible at 46 kDa. Mouse 1 was 
injected with -gal-NONOate and showed phosphorylated VASP in the lung and colon, 
it was difficult to detect and evaluate VASP phosphorylation due to low protein 
concentrations in the aorta and bladder, there was no visible VASP in the skeletal 
muscle and heart (Figure 23A left). Mouse 2 was injected with saline and served as 
a negative control and shows no to low levels of phosophorylated VASP, as expected 
(Figure 23A right). Mouse 3 was injected with -gal-NONOate and showed increased 
phosphorylated VASP in the lung and colon, it was difficult to detect and evaluate 
VASP phosphorylation due to low protein concentrations in the aorta and bladder, 
there was no visible VASP in the skeletal muscle and heart (Figure 23B left). Mouse 
4 was injected with saline and served as a negative control and shows no to low levels 
of phosophorylated VASP as expected (Figure 23B right). Note: the ApoE gene is 
not interesting for this experiment and should not influence the results. The mice 
available at the time all were heterozygous knock-outs for ApoE. After collecting some 
positive indications that -gal-NONOate can indeed induce VASP phosphorylation, we 
aimed to determine if -gal-NONOate can induce vasodilation in mice in vivo.  
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Figure 22. X-gal staining of isolated tissues from SM-CreERT2 mice and controls.  
(A) Mouse 1 (SM-CreERT2 (tg/+) x R26-lacZ (+/lacZ) x ApoE (+/-)) was treated at 12-weeks-old 
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with 1 mg of tamoxifen once a day for five days via intraperitoneal injection. Mouse 1 showed 
positive x-gal staining in the bladder and colon, weak positive staining in the lungs, and no 
obvious x-gal staining in the aorta, skeletal muscle, and heart. Positive x-gal staining is shown 
with the white arrows. (B) Mouse 2 (C57BL/6; Wild type) was x-gal negative for all tissues. (C) 
Mouse 3 (SM-CreERT2 (tg/+) x R26-lacZ (+/lacZ) x ApoE (+/-)) was treated at 12-weeks-old with 
1 mg of tamoxifen once a day for five days via intraperitoneal injection. Mouse 3 showed 
positive x-gal staining in the bladder and colon and no obvious x-gal staining in the aorta, 
lung, skeletal muscle and heart. Positive x-gal staining is shown with the white arrows. (D) 
Mouse 4 (SM-CreERT2 (tg/+) x R26-lacZ (+/+)) x ApoE (+/-)) was treated at 12-weeks-old with 1 
mg of tamoxifen once a day for five days via intraperitoneal injection. Mouse 4 was x-gal 
negative for all tissues. All x-gal stainings were performed immediately after tissue isolation 
overnight. -gal-NONOate was injected when mice 1, 3, and 4 were 15-weeks old and mouse 
2 was 14-weeks old.  
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Figure 23. -gal-NONOate-induced VASP phosphorylation. 
(A) -gal-NONOate was injected via the tail vein into a mouse expressing -galactosidase in 
cells under the control of the smooth muscle-specific SM22 promotor (SM-CreERT2 (tg/+) x R26-
lacZ (+/lacZ) x ApoE (+/-)). Saline was injected into a control mouse, mouse 2 (Wild type; 
C57BL/6). Tissue lysates from aorta (5 μg), lung (20 μg), colon (20 μg), skeletal muscle (20 μg), 
bladder (10 μg), and heart (20 μg) were stained with a VASP antibody where phosphorylated 
VASP (VASP-P, 50 kDa) and unphosphorylated VASP (VASP, 46 kDa) bands are shown with 
white arrows. GAPDH was used as a loading control. (B) -gal-NONOate was injected via 
the tail vein into a mouse expressing -galactosidase, mouse 3 (SM-CreERT2 (tg/+) x R26-lacZ 
(+/lacZ) x ApoE (+/-)) and a control mouse, mouse 4 (SM-CreERT2 (tg/+) x R26-lacZ (+/+) x 
ApoE (+/-)). Tissue lysates from aorta (5 μg), lung (20 μg), colon (20 μg), skeletal muscle (20 
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μg), bladder (10 μg), and heart (20 μg) were stained with a VASP antibody where 
phosphorylated VASP (VASP-P, 50 kDa) and unphosphorylated VASP (VASP, 46 kDa) bands 
are shown with white arrows. GAPDH was used as a loading control. Mice 1, 3, and 4 were 
treated at 12-weeks-old with 1 mg of tamoxifen once a day for five days via intraperitoneal 
injection. -gal-NONOate was injected when mice 1, 3, and 4 were 15-weeks old and mouse 
2 was 14-weeks old. Organs were isolated 20 minutes after -gal-NONOate injection. See 
section 2.15 for further information.  
 
3.2.5. -gal-NONOate-induced vasodilation in the cerebral cortex 
A window was surgically implanted above the cerebral cortex to allow for real-time 
imaging and parallel addition of substances to determine if -gal-NONOate could 
induce vasodilation in vivo. To determine if -gal-NONOate-generated NO can induce 
vasodilation in nearby vessels, real-time two-photon measurements of the cerebral 
vasculature were performed with mice expressing -galactosidase under the control 
of a neuron specific promotor (Camk2-CreBAC (tg/+) x R26-lacZ (+/lacZ)) and control 
mice without -galactosidase expression (Wnt1-Cre (tg/+) x R26-lacZ (+/+)). Indeed, 
vasodilation was observed upon the addition of -gal-NONOate (50 mM, local injection 
≈ 5 L, see section 2.7.2 for further information) in mice expressing -galactosidase in 
neurons (Figures 24D and E), while no increase in vasodilation was observed upon 
the addition of -gal-NONOate (50 mM, local injection ≈ 5 L, see section 2.7.2 for 
further information) in mice without -galactosidase expression (Figures 24H and I). 
The positive control DEA/NO (5 mM, local injection ≈ 5 L, see section 2.7.2 for further 
information) induced vasodilation independent of -galactosidase expression 
(Figures 24F,G,J,K). These data support the hypothesis of neuronal NO as an 
effector in neurovascular coupling. The data here demonstrate -galactosidase-
controlled, -gal-NONOate-induced neuronal NO generation, which diffuses to nearby 
vessels and causes a physiological response, namely vasodilation of the cortical 
arteries.  
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Figure 24. -gal-NONOtae-induced vasodilation in the cerebral cortex.  
(A) A window was surgically implanted in the cerebral cortex to measure the neurovasculature 
in real-time. (B) An image of the prepared surgery allowing for imaging of the cortical 
neurovasculature. (C) A vessel analyzed with pseudo line scan to track the vessel diameter 
over time. (D) A mouse with neuronal-specific lacZ expression (Camk2-CreBAC (tg/+) x R26-
lacZ (+/lacZ)) showed vasodilation upon the addition of -gal-NONOate (50 mM local injection 
≈ 5 L, see section 2.7.2 for further information). (E) Analysis of total vessel area for the same 
vessel in the same mouse (Camk2-CreBAC (tg/+) x R26-lacZ (+/lacZ)). Scale bars represent 
the change in vessel area (ΔA/A). The measurement is from a single representative vessel (n 
= three vessels, obtained from one mouse). (F) The same mouse (Camk2-CreBAC (tg/+) x 
R26-lacZ (+/lacZ)) showed vasodilation upon the addition of DEA/NO (5 mM, local injection ≈ 
5 L, see section 2.7.2 for further information). (G) Analysis of total vessel area for the same 
vessel in the same mouse (Camk2-CreBAC (tg/+) x R26-lacZ (+/lacZ)). Scale bars represent 
the change in vessel area (ΔA/A).The measurement is from a single representative vessel (n 
= two vessels, obtained from one mouse). (H) A mouse with no lacZ expression (Wnt1-Cre 
(tg/+) x R26-lacZ (+/+)) showed no vasodilation upon the addition of -gal-NONOate (50 mM, 
local injection ≈ 5 L, see section 2.7.2 for further information). (I) Analysis of total vessel area 
for the same vessel in the same mouse (Wnt1-Cre (tg/+) x R26-lacZ (+/+)). Scale bars 
represent the change in vessel area (ΔA/A). The measurement is from a single representative 
vessel (n = four vessels, obtained from one mouse). (J) The same mouse (Wnt1-Cre (tg/+) x 
R26-lacZ (+/+) showed vasodilation upon the addition of DEA/NO (5 mM, local injection ≈ 5 
L, see section 2.7.2 for further information). (K) Analysis of total vessel area for the same 
vessel in the same mouse (Wnt1-Cre (tg/+) x R26-lacZ (+/+). Scale bars represent the change 
in vessel area (ΔA/A). The measurement is from a single representative vessel (n = four 
vessels, obtained from one mouse). All vessels were imaged with two-photon microscopy. For 
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further information see section 2.7. Martin Thunemann (Department of Neurosciences, 
University of California, San Diego) helped with the data collection and vessel area analysis. 
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4 Discussion 
 
4.1. cGMP elevation in CGNs 
The cGMP signaling cascade influences numerous physiological processes 
across the body, such as vasodilation [2], hormone secretion [5], neurotransmission 
[6], learning and memory [10,11], sensory axon bifurcation [7], among others. This 
thesis focuses on NO-cGMP signaling in nervous systems models and how to study 
the influence of NO signaling in a cell type specific manner. By combining the FRET-
based cGMP sensor cGi500 and the fluorescent calcium indicator Fura-2AM, we were 
able to simultaneously measure cGMP and Ca2+ signals in real-time. With this method 
we revealed a crosstalk between both signaling molecules in primary CGN cultures. 
Furthermore, we successfully synthesized the compound β-gal-NONOate and 
developed a strategy that allows us to generate NO in specific cell types to analyze 
NO signaling in a cell type specific manner. 
 
4.1.1. cGMP elevation in CGNs 
Previous work has shown a relationship between cGMP and Ca2+ signaling, 
specifically a dampening of Ca2+ transients during cGMP elevation in VSMCs, 
platelets, dorsal root ganglion, olfactory bulb, endothelial cells, and other cell types 
[54,61,160-162]. Our aim was to investigate whether this crosstalk also exists in 
primary CGN cultures. CGNs are glutamatergic interneurons that provide an excitatory 
input to the molecular layer of the cerebellum. They constitute the largest neuronal 
population in the cerebellum and the largest homogeneous neuronal population in the 
entire brain [111]. CGNs serve as a model to investigate neuronal signal transduction 
in various labs across the world [111]. CGNs have been shown to express Ca2+-
permeable NMDA receptors for glutamate [111,163,164], which are essential for 
neuronal survival, and previous research has reported that upon NMDA receptor 
stimulation, NOS is activated leading to NO synthesis [164,165]. In this work, NO-
cGMP signal transduction in CGNs, as investigated via simultaneous imaging of cGMP 
and Ca2+, revealed cGK-independent cGMP/Ca2+ crosstalk in primary CGNs. 
The CGNs showed robust elevation of cGMP upon exposure to DEA/NO, but 
not during application of ANP or CNP (Figures 10A and B). These results indicated 
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that the cGMP synthesizing enzyme NO-GC is present in primary CGN cultures, while 
pGCs stimulated by ANP or CNP (GC-A and GC-B) are not. The failure to detect ANP- 
or CNP-induced cGMP increases (Figure 10B) could have been related to technical 
issues, such as an inability of the cytosolic cGi500 sensor to detect presumably 
membrane-associated cGMP pools that are generated in response to natriuretic 
peptides. However, this possibility is highly unlikely, because the cytosolic cGi500 
sensor has been successfully used to detect ANP- and CNP-induced cGMP signals in 
various other cell types including smooth muscle cells [122] and dorsal root ganglion 
neurons [155]. The concentration-response curve revealed an EC50 of 32 nM for 
primary CGNs (Figure 10C) and a DEA/NO concentration of 100 nM was used for 
further experiments to ensure a cGMP response in the CGNs.  
To verify that our cultured cells were indeed neurons, cells were stained for the 
neuronal marker -tubulin (Figure 10D). Over 95% of cells (detected by nuclear 
staining with Hoechst dye) were positive for -tubulin indicating a nearly pure 
neuronal cell culture. Since there is no widely accepted marker for CGNs, the general 
neuronal marker protein -tubulin was used to confirm neuronal identity. 
Furthermore, the cell’s morphology (small size 5-10 µm, with about four axonal 
extensions) is in agreement with previously reported CGN cultures [111,113], making 
it highly likely that the cultured cells are indeed CGNs (Figure 10D). 
We also measured DEA/NO-induced cGMP elevation in acute cerebellar slices 
(Figure 11). These results demonstrated the presence of NO-cGMP signaling in 
cerebellar cells are in line with previous work [113,166]. Recently published work has 
also employed the same cGMP imaging system in acute brain slices of cGMP sensor 
mice to demonstrate NO-induced cGMP elevations in the cerebellum, striatum and 
hippocampus [40]. In this approach, they also found robust NO-induced cGMP signals 
in the granule cell layer of the cerebellum [40], further supporting the presence of a 
NO-cGMP signaling cascade in CGNs in vivo. 
4.1.2. cGMP-Ca2+ crosstalk in CGNs 
With the knowledge that NO is able to induce a robust cGMP response in 
CGNs, we investigated a potential crosstalk between the NO-cGMP pathway and 
glutamate-induced Ca2+ signaling via simultaneous imaging of cGMP and Ca2+ in 
individual CGNs in primary cultures. As revealed with Fura-2AM and cGi500 
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measurements, Ca2+ transients in CGNs were induced by glutamate and cGMP 
generation via DEA/NO. A NO-cGMP-dependent augmentation of glutamate-induced 
Ca2+ transients in CGNs was observed during real-time simultaneous cGMP and Ca2+ 
imaging (Figure 12). Separate analysis of Ca2+ responses in the neuronal extensions 
(axons) and the cell soma (perikaryon) revealed no differences (data not shown). For 
this reason, data analysis focused on signaling in the soma due to the higher signal to 
noise ratio and greater overall analyzable area compared to the thin neuronal 
extensions.  
The glutamate-induced Ca2+ elevations were likely mediated by the NMDA 
receptor [167], but we cannot absolutely exclude other types of glutamate receptors 
as sources of Ca2+ entry. It has been reported that upon activation of Ca2+-permeable 
NMDA-type glutamate receptors in the brain nNOS is activated and NO synthesized, 
leading to cGMP generation through the activation of NO-GC [164,165]. However, in 
our FRET experiments we never observed a change in cGMP upon addition of 
glutamate (Figures 12A and B). One reason for that distinction might be that here the 
CGNs were only stimulated for a short duration (~10 s) in contrast to the other studies 
where CGNs had been exposed to NMDA agonists for minutes [164,165].  
As mentioned previously, glutamate-induced Ca2+ transients were augmented 
by DEA/NO. However, given that NO can also induce effects independent of cGMP 
[98], it was important to clarify whether the observed NO-induced [Ca2+]i augmentation 
was indeed cGMP-dependent. For that reason, we analyzed CGNs from knockout 
mice lacking functional NO-GC. In line with our hypothesis, exposure of NO-GC KO 
CGNs to DEA/NO did not increase [cGMP]i and did not augment glutamate-induced 
[Ca2+]i transients (Figures 12C-E). These results strongly supported the notion that 
NO augmentation of glutamate-induced Ca2+ responses in CGNs is cGMP dependent 
and specifically mediated via NO-GC. 
4.1.3. cGMP analogues to investigate cGMP-Ca2+ crosstalk in CGNs 
To further determine the importance of cGMP in the potentiation of glutamate-
induced elevation of [Ca2+]i, we exposed CGNs to the membrane-permeable cGMP 
analogues 8-Br-cGMP and 8-pCPT-cGMP. Both analogues are able to activate cGMP 
downstream targets [168,169]. Indeed, both cGMP analogues enhanced glutamate-
induced elevation of [Ca2+]i (Figure 13). These results support the notion that NO 
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potentiates glutamate-induced Ca2+ transients in murine CGNs via activation of 
NO-GC and synthesis of cGMP. Interestingly, a recent study reported that the slow 
alcohol-induced increase of [Ca2+]i in CGNs was suppressed by pre-incubation of the 
cells with 8-Br-cGMP [170]. This would suggest that activation of cGMP signaling in 
CGNs can both increase and decrease [Ca2+]i depending on the type of Ca2+ signal. 
It has to be mentioned that in the experiments with 8-Br-cGMP, the peak height 
ratio of the 2nd over the 1st Ca2+ transient under control conditions (Tyrode, no cGMP 
stimulation) was 1.6 (Figure 13A). This value was higher than the control ratios 
obtained in the other experiments, which were 0.8-1.0 (Figures 12C and F; Figure 
13B). The variability of control transients might be related to different growth states of 
different CGN cultures. However, it is important to note that control cells (treated with 
Tyrode) and experimental cells (treated with DEA/NO or cGMP analogues) were 
always measured side-by-side with the same batch of cells. Therefore, the variability 
in the control ratio between different CGN cultures is not a confounding factor in these 
experiments.  
While 8-Br-cGMP and 8-pCPT-cGMP are commonly used to activate cGKs, it 
is important to note that these cGMP analogues also bind to and modulate the activity 
of other cGMP downstream targets such as PDEs and CNG channels [171,172]. 
Indeed, previous work has reported a slow increase in resting [Ca2+]i in Fura-2 loaded 
rat CGNs upon the addition of 8-Br-cGMP, suggesting the presence of functional CNG 
channels [115]. However, under our experimental conditions, resting [Ca2+]i was not 
affected by NO-induced endogenous cGMP (Figure 12B) or two cGMP analogues, 8-
Br-cGMP and 8-pCPT-cGMP. Thus, it is unlikely that the augmentation of glutamate-
induced [Ca2+]i by these cGMP analogues was related to activation of CNG channels. 
Also, while cultured rat CGNs have been documented to express hyperpolarization-
activated cyclic nucleotide-gated channels as determined by mRNA analysis [114], 
these ion channels are principally activated by cAMP and not cGMP. For this reason, 
it is unlikely that they were directly influenced by our test compounds.  
 
4.1.4. The role of cGKs in cGMP-Ca2+ crosstalk in CGNs 
A possible cGMP downstream target influencing cGMP/Ca2+ crosstalk could 
be cGKI or cGKII. Previous work with genetically modified mice has demonstrated 
important roles of cGKI in the brain, from modulation of synaptic plasticity in 
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hippocampal neurons [173] and cerebellar Purkinje cells [100] to the regulation of 
sleep-wake activity [174]. Moreover as mentioned previously, cGKI mediates cGMP-
Ca2+ crosstalk, specifically by dampening of Ca2+ transients during cGMP elevation, 
in VSMCs, platelets, dorsal root ganglion, olfactory bulb, endothelial cells, and other 
cell types [54,61,160-162,175]. Since activation of cGKI in these cells has been 
reported to dampen Ca2+ transients [176-178], cGKI is likely not the effector of the 
NO-cGMP-mediated augmentation of [Ca2+]i observed in CGNs. Indeed, Western blot 
analysis did not detect cGKI protein expression in our primary mouse CGNs (Figure 
14). More surprisingly, was that cGKII protein expression was also not found with 
Western blot analysis of our primary CGNs (Figure 15). These findings contrast with 
previous studies of the Torres lab where they reported cGKI mRNA and protein and 
cGKII mRNA in CGNs [113,179]. Moreover, these studies demonstrated a role of 
cGKI and cGKII in synaptic vesicle recycling in CGNs [166,180]. The discrepancy 
could be explained by methodological differences. For example, we did not analyze 
mRNA levels but rather used highly specific antibodies for cGKI and cGKII, which 
were validated with respective knockout tissues (Figures 14 and 15). Torres and 
colleagues used a different cGKI antibody, with presumably different specificity and 
sensitivity for Western blotting, and did not show data from the respective knockout 
control. They did not analyze cGKII expression at the protein level. Antibody quality 
has a large influence over conclusions and if this work has been conducted without 
proper antibody validation then we could have erroneously concluded cGKII 
expression in the CGN lysates (Figure 15B). 
It is interesting to note that while we were not able to detect cGKI and cGKII in 
our CGN lysates, both proteins were readily detected in extracts of whole cerebellum 
(Figures 14 and 15A). This suggests that cell types other than CGNs express cGKI 
and/or cGKII in the cerebellum. Indeed, immunohistochemical staining of cerebellar 
sections showed strong expression of cGKI in cerebral vessels and Purkinje neurons, 
but no evidence for its expression in CGNs [57,100]. cGKII has been detected in low 
levels in Purkinje neurons and occasionally in the cerebellum’s granular cell layer 
[181]. Another reason for discrepant results regarding the expression and functional 
relevance of cGKs and CNG channels could be that CGNs develop differential 
expression of these cGMP pathway components upon culturing over time. Indeed, 
the Torres lab has reported that both CNG channels and cGKs expression varies with 
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the number of days the CGNs have been in culture [113,115]. Another reason for the 
discrepancy between our results and the data obtained by the Torres lab might be 
the species used. Most of the previous studies of NO-cGMP signaling in CGNs as 
well those from the Torres lab were done in cells isolated from rats, while we prepared 
primary CGN cultures from mice. Our studies, as well as those by Torres et al., were 
performed with CGNs isolated from young (P7) mice or rats. In summary, differences 
in antibody selectivity and sensitivity, culture conditions/times as well as species 
differences might account for variances in protein expression observed in our studies 
and those by Torres and co-workers. Even with these discrepancies, it seems likely 
that cGKs have no role in the observed cGMP-dependent augmented Ca2+ transients 
in our CGN models. Since cGMP signaling in the brain appears to dramatically 
change with aging [182], one must be careful when extrapolating the findings to 
CGNs in the adult cerebellum. 
 
 
4.1.5. cGMP degradation in CGNs via PDEs 
cGMP degradation occurs via PDEs and many of the eleven PDE families have 
been reported in the CNS [69,79,80]. To our knowledge, the PDEs involved in cGMP 
degradation in CGNs have not been previously characterized. With our FRET-based 
cGi500 sensor it was possible to investigate the role of PDEs in cGMP degradation in 
primary CGNs in real time (Figures 16A and B). NO-induced cGMP levels were not 
affected by inhibitors of PDE1, 2, and 3, while they were strongly potentiated by 
Zaprinast, which inhibits PDE5, 6, 9, 10, and 11. PDE5 inhibition via sildenafil only 
resulted in a small cGMP increase (Figure 16B). 
Previous work has proposed that Ca2+ entry might decrease NO donor-induced 
cGMP levels in CGNs via activation of Ca2+/calmodulin-stimulated PDE1 [183], but we 
did not observe this (Figures 13A and B). Moreover, we did not detect functional 
PDE1 in our functional studies (Figure 16B). The presence of PDE1 could be masked 
by compensatory PDEs that are able to sufficiently degrade cGMP in CGNs even when 
PDE1 is rendered non-functional by a PDE inhibitor. For this reason, we cannot 
completely exclude the role of PDE1 as suggested by previous work [183]. Our 
findings are consistent with the reported expression of PDE9 in rat CGNs [184], but 
not PDE2, in CGNs of the human brain [185]. Previous research performed in rodents 
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and humans has suggested that PDE9, 10 and 11 play a role in neurological diseases. 
For example, PDE9 was shown to be involved in bipolar affective disorder [81], PDE10 
in social interaction, schizophrenia, and bipolar disorder [82-84] and PDE11 in major 
depression [85]. However, neither PDE6 nor PDE11 are expressed in the cerebellum 
[69,79,186].  
Since both NO-GCs and pGCs can generate cGMP, researchers have 
theorized that two separate pools of cellular cGMP exist. The NO-GC generated pool 
is believed to be more global, while the pGC-generated pool is thought to be localized 
to the membrane. For this reason, different PDEs might more readily influence one of 
the pools depending on their cellular localization. For example, PDE9 appears to be 
localized to the membrane and nuclear fractions of cerebellar tissue [187]. For this 
reason, PDE9 has been suggested to specifically regulate cGMP pools generated by 
pGCs, but not by cytosolic NO-GC in heart muscle cells [188]. Given this data, it could 
be that PDE9 regulates the local cGMP pool and because cGMP was only elevated in 
CGNs upon stimulation of NO-GC (the presumably global cGMP pool generator), 
PDE9 might not be the major actor of cGMP degradation in CGNs. Therefore, we 
propose that PDE5 and especially PDE10 are the most likely candidates that degrade 
NO-induced cGMP pools in murine CGNs. In the future, experiments with more 
specific PDE targeting molecules should be done (e.g. PDE10 inhibitor PQ-10 [189]). 
As stated previously, it is important to note that the application of specific PDE 
inhibitors (targeting only one PDE family) cannot exclude its existence in a given cell 
due to potential compensatory interactions of other cGMP-degrading PDEs that could 
effectively mask the single blocked PDE.  
Analysis of the messenger RNA (mRNA) levels via quantitative polymerase 
chain reaction (qPCR) studies could reveal if other cGMP effectors are expressed in 
CGNs, but it is important to note that there is often a low correlation between cellular 
mRNA levels and actual protein expression, as determined by Western blot, which 
reduces the quality of qPCR data [190]. Excitingly, the data shown here are derived 
from real-time visualization of the cGMP signaling pathway in living cells and are a 
prime example of the need to investigate signaling pathways under dynamic 
conditions, such as in living cultures, tissues and animal models. This methodology 
contrasts with the majority of cGMP signaling research, which tends to investigate 
cGMP levels as an endpoint rather than the dynamic process that it clearly is. 
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4.1.6. Outlook for cGMP signaling in CGNs 
The above discussed data demonstrate the power of real-time, simultaneous imaging 
of cGMP and Ca2+ combined with traditional biochemical experiments. Here we 
identified the presence of a cGK-independent NO-cGMP signaling cascade that 
potentiates glutamate-induced Ca2+ transients in murine CGNs, and a Zaprinast-
sensitive degradation of cGMP in these cells. Further research is required before the 
downstream cGMP target(s) is(are) identified. Inhibitor experiments during real-time 
imaging could help to elucidate further signaling components, for example ion channel 
inhibitors like MK-801 for NMDA receptors [191] or L‐cis‐diltiazem for CGN channels 
[192]. The findings reported here deepen our mechanistic understanding of NO-cGMP 
signaling in the CNS (Figure 25). The cGMP-Ca2+ crosstalk reported here likely 
influences neurotransmitter-stimulated functions of CGNs and perhaps other neuronal 
cell types and might be targeted by cGMP-modulating medications to treat 
neurological disorders. 
 
Figure 25. Summary and outlook of the CGN findings. 
In CGNs, both ANP and CNP do not elevate cGMP levels in CGNs indicating that GC-A and GC-B are 
not expressed in CGNs (red crosses). Conversely, NO does activate NO-GCs resulting in conversion 
of GTP into cGMP. The observed cGMP/Ca2+ crosstalk is not a result of NO off targets (red cross), but 
Discussion 
 
84  
is rather cGMP-dependent. Said crosstalk is not modulated by cGKI or cGKII because neither were 
detected in our CGN cultures (both are crossed out). cGMP is most likely degraded to GMP by PDE5 
or 10 in CGNs. Although CNG channels appear unlikely to mediate the observed cGMP/Ca2+ crosstalk, 
their potential role should be investigated with real-time imaging and pharmacological tools. The cGMP-
effector protein(s) that mediates the observed cGMP/Ca2+ crosstalk has yet to be identified (two arrows 
with a question mark). 
 
Furthermore, several imaging-based studies have identified important functions 
of cGMP, cAMP, and Ca2+ in neuronal cells and, interestingly, complex relationships 
between the spatiotemporal dynamics of these signaling molecules. For instance, 
reciprocal regulation of cAMP and cGMP regulates axon/dendrite formation in 
hippocampal neurons [193]. In that study, FRET imaging showed that alterations in 
the amount of cAMP resulted in inversely proportional changes in the amount of 
cGMP, and vice versa, through the activation of PDEs and protein kinases. Another 
study showed that the NO-cGMP pathway inhibits transient cAMP signals through the 
activation of PDE2 in striatal neurons [74,194]. Recently, an interplay among cGMP, 
cAMP, and Ca2+ was reported in olfactory sensory neurons [195] and dorsal root 
ganglion neurons [196,197] as well as a correlation of this signaling crosstalk with 
axonal pathfinding and neurotransmitter release. For these reasons, we postulate that 
the identified cGMP-Ca2+ crosstalk in CGNs also involves cAMP. In the future, it will 
be interesting to monitor cGMP/cAMP and cAMP/Ca2+ simultaneously in individual 
CGNs with the use of spectrally compatible fluorescent indicators that are currently 
under development. With such experiments, one could test the hypothesis that NO-
cGMP signaling modulates cAMP levels, presumably via regulation of cAMP-
degrading PDEs, and that cAMP in turn regulates glutamate-induced Ca2+ transients 
in CGNs. 
 
 
4.2. Cell type specific generation of NO with -gal-NONOate 
The results from the CGN experiments demonstrated the power of the tools that 
exist to investigate the role of signaling molecules in individual cells in culture. 
However, while it is relatively easy to prepare a pure cell culture with a specific cell 
type to investigate signaling cascades, it is more difficult to investigate said signaling 
cascades in specific cells in tissues or living animals. The cell type specific generation 
of NO is a possible solution to investigate the role of NO-cGMP in a more defined 
manner. The data reported in this thesis describe such a new method enabling cell-
specific NO generation and subsequent cGMP elevation. 
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To our knowledge, this is the first report of cell type specific NO generation. We 
have developed this strategy by employing -gal-NONOate. The closest experiments 
to those reported here involved the combination of -gal-NONOate with implantable 
biomaterials to generate local NO release [198,199]. These grafts are designed to be 
inserted subcutaneously and, as such, the -gal-NONOate generated NO is locally 
released, but not by specific endogenous cell types. Other researchers have 
demonstrated NO release with -gal-NONOate in lacZ expressing cells. These authors 
utilized -gal-NONOate to enable NO release in cultured tumor cells and suggested it 
could be combined with cisplatin treatment to increase tumor cell death [200]. The 
study used cell lines containing the lacZ gene and it is not clear how this would 
translate to a mammalian therapy where the lacZ gene is essentially entirely absent.  
The research presented in this thesis focused on -gal-NONOate as an ideal 
tool to enable cell type specific NO generation in vivo allowing for exquisite 
spatiotemporal investigation of the role of NO-cGMP signaling in biological systems. 
For example, it is possible to investigate the cell type specific role of NO in complex 
biological processes, such as learning and memory. As mentioned previously, cGMP 
signaling has been shown to play a role in LTP in the amygdala and hippocampus and 
in LTD in the cerebellum [10], but the detailed relevance of this signaling pathway in 
specific cell types has not been investigated. Another difficult to test hypothesis is that 
NO could act as a retrograde messenger and travel from the postsynapse across the 
synaptic cleft to the presynapse, or anterogradely, and increase presynaptic cGMP 
levels via NO-GC activation [201]. Numerous NO-releasing molecules have been 
developed [140], but they lack cell type specificity and, until now, none have been 
utilized to enable cell-specific NO generation in vivo. To perform these experiments, 
we first needed to synthesize the compound -gal-NONOate. 
 
4.2.1. Synthesis of -gal-NONOate 
Due to high costs and low availability from commercial sources, -gal-NONOate 
was synthesized by the Feil lab in collaboration with the Stafforst Lab and Ziegler Lab. 
The synthesis of -gal-NONOate was performed in 5-steps (Figure 18) and resulted 
in an overall yield of ~6% (Figure 18). The compound’s molecular structure was 
investigated via 1H NMR (Figure 17). Due to the complex nature of the molecule, it 
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was not easily discernable from the 1H NMR structure alone, but the reported values 
are in general agreement with previously published values [141]. Investigation of the 
chemical’s ability to release NO was ultimately validated in biological systems as 
discussed in the following sections.  
 
4.2.2. -gal-NONOate-induced cGMP responses in VSMCs 
It was first crucial to determine that our newly synthesized compound released 
NO in a validated cell culture system. β-gal-NONOate was applied to primary VSMCs 
expressing the cGi500 sensor (Figures 19A and 20A) and shown to induce cGMP 
elevation in the presence of β-galactosidase (Figures 19C-E), but not under the same 
conditions in VSMCs lacking β-galactosidase (Figures 20C and D). X-gal staining was 
performed to determine β-galactosidase expression (Figures 19B and 20B). VSMC 
cultures were used as a cell model due to better rates of transfection when compared 
to neuronal cultures, which are notoriously resilient to transfection via traditional 
methods likely due to their post-mitotic nature [202]. Previous work with VSMCs 
revealed an increase in [cGMP]i in nearly 100% of VSMCs upon the addition of 
DEA/NO (100 nM) [122], as observed in the experiments reported here (Figures 19C-
E; Figures 20C and D). As expected, since only a portion of VSMCs (7%) expressed 
β-galactosidase (Figure 19B), [cGMP]i elevation occurred in only some VSMCs 
(62%) upon the addition of β-gal-NONOate and with varying efficiency (Figures 19C-
E). No elevation in [cGMP]i was observed upon the addition of β-gal-NONOate in 
VSMC cultures lacking β-galactosidase indicating that there is no spontaneous release 
of NO from -gal-NONOate (Figures 20D and E). As expected, the positive control 
DEA/NO produced clear cGMP elevations in both conditions (Figures 19C,D, and E; 
Figures 20C and D). The intensity of the cGMP response varied across VSMCs as 
observed upon exposure to the control stimulus DEA/NO (Figures 19C-E; Figures 
20C and D). This might be caused by differential expression of NO-GCs, which could 
influence VSMC response-sensitivity to NO. Another possible explanation for variable 
cGMP responses is the differential expression of cGi500 across the cells, which can 
be inferred from the YFP intensity of the individual cells (Figure 19A; Figure 20A). 
This observation demonstrates the strength of real-time imaging in individual cells, 
which allows researchers to investigate the heterogeneity of phenotypes across cells 
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of the same type. Interestingly, previous work has suggested that cGMP is capable of 
moving across cells, perhaps via gap junctions, which could further influence cGMP 
response strengths in VSMCs [203]. 
Given that β-gal-NONOate did not induce cGMP elevation in control cultures 
(Figure 20), these results demonstrate β-gal-NONOate’s ability to selectively release 
NO under the control of β-galactosidase. Similar research reported light-controlled 
release of NO using a photocaged NONOate substance in VSMCs [204]. Such a light-
controlled methodology is powerful and allows for spatiotemporal release of NO. The 
here reported β-gal-NONOate methodology allows for NO generation under 
spatiotemporal control and in a cell-specific manner. 
 
4.2.3. -gal-NONOate-induced cGMP responses in cerebellar tissue slices 
As mentioned previously, cGMP has been shown to play a role in LTP in the 
amygdala and hippocampus and in LTD in the cerebellum [10], but the role of specific 
cell types has remained elusive. By combining tissue-specific Cre mouse lines with 
cGi500 sensor mice and lacZ mice, it is possible to obtain cell type specific expression 
of both the cGi500 sensor and the lacZ gene. Here, we employed the L7-Cre mouse 
line that has been shown to induce recombination in Purkinje cells [100,145,205]. By 
combining these mouse lines and using -gal-NONOate, it is possible to generate NO 
release only in Purkinje cells and verify this in real time with the cGi500 sensor by 
visualizing the cGMP dynamics in individual Purkinje neurons. 
Here we measured cGMP in Purkinje cells expressing cGi500 (Figures 21A 
and D) under continuous superfusion. Indeed, β-gal-NONOate was shown to induce 
cGMP elevation in Purkinje neurons in β-galactosidase positive cerebellar slices (L7-
Cre (tg/+) x R26-lacZ (lacZ/L2) x R26-cGi500-L2 (lacZ/L2)) (Figure 21C), but not 
under the same conditions in Purkinje neurons in β-galactosidase negative cerebellar 
slices (L7-Cre (tg/+) x R26-lacZ (L2/+) x R26-cGi500-L2 (L2/+)) (Figure 21F). 
However, because the control experiment (L7-Cre (tg/+) x R26-lacZ (L2/+) x R26-
cGi500-L2 (L2/+)) used a lower concentration of β-gal-NONOate (5 M vs 25 M) 
(Figure 21F), spontaneous NO release from β-gal-NONOate in acute tissue slices 
cannot be excluded. DEA/NO produced clear cGMP elevations in both conditions 
(Figures 21C and F). X-gal staining was performed to determine β-galactosidase 
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expression (Figures 21B and E). These results are in line with other work that 
investigated NO-cGMP signaling and reported cGMP elevation in Purkinje cells [40]. 
Our data demonstrate the -gal-NONOate strategy’s capacity to induce cell-specific 
NO generation in tissue slices. After these results, we moved to determine if 
downstream cGMP effectors are influenced in vivo by injecting β-gal-NONOate into 
transgenic mice.  
 
4.2.4. -gal-NONOate-induced VASP phosphorylation in vivo 
Due to the plethora of research done on NO-cGMP signaling in the smooth 
muscle cells [2], we first tested -gal-NONOate’s ability to phosphorylate VASP, a 
cGMP downstream target, in mice that express the lacZ gene under the control of 
smooth muscle-specific SM22 promotor (SM-CreERT2 (tg/+) x R26-lacZ (+/lacZ)) 
[147]. In this model, if cGMP levels were successfully elevated upon addition of -gal-
NONOate then cGKI should be activated in VSMCs, which should induce VASP 
phosphorylation. 
-gal-NONOate was injected via the tail vein of mice expressing -
galactosidase in smooth muscle cells (SM-CreERT2 (tg/+) x R26-lacZ (+/lacZ) x ApoE 
(+/-)) and control mice without lacZ expression (SM-CreERT2 (tg/+) x R26-lacZ (+/+) x 
ApoE (+/-) or C57BL/6). The mice were then sacrificed after 20 minutes and the organs 
(heart, aorta, colon, bladder, skeletal muscle from the torso, and lungs) were isolated 
for x-gal staining to determine -galactosidase expression in the isolated tissues 
(Figure 22) as well as Western blotting to detect both VASP and phosphorylated 
VASP levels. Positive x-gal staining was observed in the bladder and colon of lacZ 
expressing mice (Mouse 2 and 4; Figures 22B and D), as well as the lung of one 
mouse to a lesser extent (Mouse 2; Figures 22B). Indeed, we observed increased 
VASP phosphorylation in the colon and lung isolated from -galactosidase positive 
mice (Mouse 1 and 3; Figures 23A and C) compared to the control mice lacking lacZ, 
which showed no phosphorylated VASP (Mouse 2 and 4; Figures 23B and D). The 
bladder and aorta signals are weak due to low protein concentration making it difficult 
to draw conclusions from these data (all mice; Figure 23). Both skeletal muscle and 
heart were negative for x-gal staining in all mice and did not show a band for VASP 
suggesting the protein is not present in these tissues (all mice; Figures 22 and 23). 
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While these results should be repeated to improve the quality of the data, the 
increased VASP phosphorylation in the colon and lung isolated from  
-galactosidase positive mice (Mouse 1 and 3; Figures 23A and C) compared to the 
control mice lacking lacZ (Mouse 2 and 4; Figures 23B and D) support the hypothesis 
that -gal-NONOate is able to induce NO-cGMP signaling in vivo. We then 
investigated if -gal-NONOate was able to induce a physiological response in vivo, 
namely vasodilation. 
 
4.2.5. -gal-NONOate-induced vasodilation in the cerebral cortex 
Here, we demonstrated the ability of β-gal-NONOate to induce NO generation 
in neurons resulting in nearby vasodilation in living mice. Neuronal activity in the 
human brain can be measured noninvasively using Blood Oxygenation Level 
Dependent (BOLD) contrast in functional magnetic resonance imaging (fMRI). It has 
been hypothesized that BOLD signals reflect biochemical signaling processes which 
affect the cerebral vasculature through signaling cascades summarized as 
‘neurovascular coupling’ [109,206]. However, the exact biochemical mechanisms 
which couple neuronal activity with vascular responses leading to regional changes in 
blood flow and oxygenation are far from understood. If elucidated, the molecular 
underpinnings of BOLD-fMRI would form an important framework to assess neuronal 
function in humans for both biochemical research and diagnostic purposes.  
Previous research has demonstrated that NO increases cerebral blood flow, 
but this evidence lacks mechanistic understanding [109]. It has been postulated that 
NO released from neurons could diffuse to nearby vessels resulting in vasodilation 
and thus increase nutrient supply to the neural region [109]. Traditional methodology 
cannot easily investigate this hypothesis because conventional NO-releasing 
substances are not cell specific as previously stated [140]. Here, we surgically 
implanted a window in the cerebral cortex (Figures 24A and B) and conducted 2-
photon imaging of blood vessels in the cerebral cortex of mice expressing lacZ under 
the control of a neuronal specific promoter (Camk2-CreBAC (tg/+) x R26-lacZ 
(+/lacZ)) to investigate the feasibility of NO as a modulator of neurovascular coupling 
(Figure 24). The vessels were analyzed with pseudo line scan or total area (Figures 
24C,E,G,I,K) β-galactosidase was only expressed in neurons and not in the 
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vasculature in these mice [148]. Given the gaseous nature of NO, it can diffuse across 
cell membranes and enact physiological effects on nearby cells, such as blood 
vessels. Indeed, upon microinjection of β-gal-NONOate (50 mM) into the cerebral 
cortex we observed vasodilation of nearby vessels in mice expressing lacZ in neurons 
(Figures 24D and E), but not in mice lacking -galactosidase expression (Figures 
24H and I). The positive control DEA/NO (5 mM) induced vasodilation in both mice 
(Camk2-CreBAC (tg/+) x R26-lacZ (+/lacZ); and Wnt1-Cre (tg/+) x R26-lacZ (+/+)) 
(Figures 24F,G,J,K). These data provide the first in vivo evidence that -gal-
NONOate generated NO can induce a physiological effect, namely vasodilation, and 
support the notion of NO as an effector molecule in neurovascular coupling. These 
data demonstrate the power of cell type specific NO release and how we can use it to 
address previously difficult to investigate scientific questions. 
 
4.2.6. Outlook for -gal-NONOate as a tool to investigate the role of NO-cGMP 
signaling in behavior  
With β-gal-NONOate assisted cell-specific NO release, it is possible to more 
precisely elucidate the role of the NO-cGMP pathway in specific cell types during 
dynamic processes such as learning. The -gal-NONOate methodology could also 
inform researchers about the diffusion area of NO by breeding R26-lacZ mice with Cre 
mice under the control of a cell specific promotor and R26-cGi500-L1 mice to produce 
global cGi500 sensor expression, but cell specific lacZ expression. Then NO would be 
released from specific cell types and cGMP could be visualized in neighboring cells 
that do not generate NO. A caveat to this type of study is that only cells expressing 
NO-GC would be expected to show elevated cGMP levels upon exposure to NO, thus 
limiting the strength of such an experiment.  
As stated before, NO is believed to influence LTD in Purkinje neurons, but the 
exact role is still debated [100,166,179,207-211]. One could investigate this 
hypothesis based on the findings presented here using a mouse containing the cGi500 
sensor and lacZ under the control of a Purkinje cell specific promoter (L7-Cre (tg/+) x 
R26-cGi500-L2 (L2/lacZ) x R26-lacZ (L2/lacZ)), the same mouse line as used in our 
cerebellar tissue slice experiments (Figure 21). The influence of NO-cGMP signaling 
in Purkinje cells on LTD can be investigated by motor learning paradigms, such as a 
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'balance beam test' [212]. Moreover, β-gal-NONOate could be remotely injected at 
time points defined by the researchers via a surgically implanted intracranial pump to 
investigate the role of NO-cGMP at different phases of learning (i.e. encoding, storage 
and recall) (Figure 26). An intracranial pump might be necessary because it is not 
clear if β-gal-NONOate crosses the blood brain barrier. A potential experiment to 
determine to what extent, if at all, β-gal-NONOate crosses the blood brain barrier 
would be injection into a mouse (i.e. tail vein injection) and then after some time (~20 
min) isolate the cerebral spinal fluid and perform a mass spectrometry analysis. 
Western blot analysis of cGMP influenced neuronal markers (e.g. CREB) is also a 
possibility.  
 
Figure 26. Controlled intracranial injection of -gal-NONOate to investigate the role of NO 
signaling in behavior paradigms.  
It is possible to inject -gal-NONOate into the brain via a controllable pump (e.g. iPRECIO® pump) that 
the researcher can activate at specified time points. This could be done in a mouse line with cell-specific 
Cre expression to enable lacZ and thus -galactosidase expression only in the desired cell type (e.g. 
Purkinje cells, the blue cells in mouse cerebellum). Behavioral paradigms could then be employed to 
investigate the cell-specific role of NO signaling in learning and memory.  
 
 
If -gal-NONOate influences motor learning when compared to control mice -- 
those without lacZ -- then tools can be employed to determine if NO works via a cGMP-
dependent or independent manner, for example by inhibiting NO-GC either with a KO 
mouse line or pharmacologically (i.e. ODQ). However, it is important to note that ODQ 
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is not a perfect inhibitor of NO-GC as demonstrated by Friebe and colleagues who 
showed that cGMP elevation is possible to achieve with high NO concentrations even 
in the presence of ODQ [213]. As reported by Peters and colleagues, NO-cGMP 
signaling is present in various neuronal regions [40]. With the Cre/loxP system under 
the control of cell type specific promotors, it is possible to target specific brain cells, 
such as the Purkinje cells as described previously (Figure 21). With these the relevant 
Cre mouse lines, it is possible to investigate the role of NO-cGMP signaling in learning 
and memory (e.g. fear conditioning, motor learning, spatial learning, memory recall, 
and others) in different neuronal cell types.  
The role of cGMP in neural plasticity suggests that future cGMP-modulating 
medications could be used to treat neurological disorders. For example, researchers 
have demonstrated that the PDE5 inhibitor sildenafil can improve learning in a rat 
model of hepatic encephalopathy which has dysfunctional cGMP signaling and neural 
deficits [214]. Similar research reported that PDE9 inhibition also results in memory 
enhancement in wild type rodents [215]. Indeed, a number of papers have implicated 
PDE inhibitors in cognitive enhancement in rats [216-220], mice [221-223] and even 
macaques [224]. More preclinical and clinical trials need to be done before these drugs 
make it into human use as it is important to completely understand the role of cGMP 
signaling in the CNS.  
The dearth of information about cell type specific influences on cognitive 
processes highlights the importance and strength of our -gal-NONOate method. With 
this new strategy it is now possible to investigate NO-cGMP signaling in specific cell 
types at the molecular and behavioral levels. However, it is important to note that the 
lacZ gene itself can confound results. For example, researchers have identified an 
influence of lacZ expression on hippocampus-dependent memory in [225]. In short, 
the study investigated the influence of lacZ expression on Cre reporter mouse lines in 
behavioral tests, such as acoustic startle response, fear-conditioning, and 
hippocampus-dependent spatial learning. The researchers reported decreased 
hippocampus dependent spatial learning in mice that showed lacZ expression in the 
cortex and hippocampus (R26-Nex-Cre (tg/+) x R26-lacZ (+/lacZ)) when compared to 
wild type controls. This study has important implications for mouse research given that 
many laboratories use lacZ as a reporter gene to determine the temporal and spatial 
expression of gene of interest [149,226,227]. LacZ has also been used as a reporter 
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to investigate to investigate addiction behavior and learning and memory by placing 
lacZ under the control of the neuronal activity-associated promotor Fos. The method 
has been applied in mouse, rat and monkey models [228-230]. Furthermore, the  
-galactosidase protein is analogous to mammalian senescence-associated  
-galactosidase and because protein accumulation is associated with 
neurodegeneration, constitutive expression of lacZ has been hypothesized to induce 
neuronal death. Indeed, the previously mentioned study did find reduced hippocampal 
volume in lacZ expressing mice [225]. Other research has also shown an association 
between YFP accumulation and neurodegenerative effects demonstrating the 
potential side effects of transgenic gene expression in the nervous system [231]. To 
control for the potential influence of genetic tools on results, it is important to compare 
the modified mice with wild type control mice. 
Other strategies have been developed for cell type specific investigation of 
biological processes. One such strategy employed genetic mouse models and 
pharmacological agents to investigate the specific roles of dopamine receptor 1 (D1) 
or dopamine receptor 2 (D2) in neuronal culture, brain tissue slices and a mouse model 
of Parkinson’s disease [232]. The researchers used DART (drugs acutely restricted by 
tethering), which is a technique capable of capturing and tethering drugs to the surface 
of specific cells. The cell specific ligands bind molecules and spatially restrict their 
action to that one cell providing researchers with the ability to make conclusions about 
the role of specific cell types in behavioral paradigms. This methodology has 
similarities to the -gal-NONOate and lacZ cell specific NO generation strategy 
described here. For example, the cell specificity is also derived from a cell type specific 
promotor using the Cre/loxP system. It can be used as a reference paper for future 
behavioral work with -gal-NONOate. 
We have demonstrated the power of this method in cell culture, tissue slices 
and in vivo. While this work primarily emphasizes the use of -gal-NONOate in the 
brain, with the various cell type specific mouse lines available, it is possible to conduct 
experiments to investigate the cell type specific role of NO-cGMP signaling in both the 
nervous system and other biological systems. 
References 
 
94  
5 Appendix 
 
5.1. Polymerase chain reaction protocols 
Table A1. Primer Sequences 
Primer  Sequence 
BB01  CTCTGCTGCCTCCTGGCTTCT 
BB02  CGAGGCGGATCACAAGCAATA 
BB03  TCAATGGGCGGGGGTCGTT 
BB19 AAGATGCTGAAGGGAAGGATGC 
BB20 CAGCCCAAAGAAACAAGAAGAAAG 
BB21 GATGTGGGATTGTTTCTGAGGA 
Cre800 GCTGCCACGACCAAGTGACAGCAATG 
Cre1200 GTAGTTATTCGGATCATCAGCTACAC 
RF127 GCGAAGAGTTTGTCCTCAACC 
Cam k1 GGTTCTCCGTTTGCACTCAGGA 
Cam k2 CCTGTTGTTCAGCTTGCACCAG 
Cam k5 CTGCATGCACGGGACAGCTCT 
Table A2. Polymerase chain reaction conditions 
PCR  Primer Conditions 
L7-Cre; Wnt1-Cre; 
SM-CreERT2 
Cre800 
Cre1200 
95 °C   5 min 
95 °C   10 sec 
58 °C   30 sec          35x       
72 °C   30 sec 
72 °C   5 min 
R26-cGi500-L1 and 
R26-cGi500-L2 
BB01 
BB02 
BB03 
95 °C   5 min 
95 °C   10 sec 
61 °C   30 sec          35x       
72 °C   30 sec 
72 °C   5 min 
lacZ 
BB01 
BB02 
RF127 
95 °C   5 min 
95 °C   10 sec 
61 °C   30 sec          35x       
72 °C   30 sec 
72 °C   5 min 
NO-GC KO 
BB 19 
BB 20 
BB 21 
94 °C   3 min 
95 °C   60 sec 
60 °C   45 sec          30x       
72 °C   60 sec 
72 °C   7 min 
Camk2-CreBAC 
Cam k1 
Camk2 
Camk5 
95 °C   2 min 
95 °C   30 sec 
66 °C   30 sec          45x       
72 °C   90 sec 
72 °C   10 min 
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5.2. Construct map of pFRTβ-gal 
 
 
 
 
Figure A1. Construct map of pFRTβ-gal. Map provided by Prof. Dr. Robert Feil. 
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